<html xmlns="http://www.w3.org/1999/xhtml"> <head> <style type="text/css">
      	     		 
      	    a                          {background : #ffffff; }
      	    article                    {border-style : dotted; border-width : 2px; }
		 	
		 	div                        {background : #ffffcc;}
		 	div.abstract-title         {font-weight : bold ; font-size : 16pt;}
		 	div.ack                    {border-style : solid ; border-color : red; margin : 2em; }
		 	div.article-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.boxed-text             {margin : 5em; border-style : solid;}
		 	div.contrib-group          {margin : 1em; }
		 	div.fig                    {border-style : solid; border-width : 2px; margin : 2em; }
		 	div.funding                {font-weight : bold ; font-size : 16pt;}
		 	div.given-names            {font-style : italic;}
		 	div.intro                  {border-style : inset; margin : 5px;}
		 	div.introduction           {border-style : inset; margin : 5px;}
		 	div.journal-meta           {border-style : solid; border-width : 1 pt; margin 1em;}
		 	div.journal-title-group    {background : #ffeeee;}
		 	div.article-title          {font-weight : bold ; font-size : 18pt;}
		 	div.kwd                    {font-style : italic}
		 	div.meta-name              {font-weight : bold ; font-size : 16pt;}
		 	div.name                   {font-weight : bold;}
		 	div.alt-title              {font-style : italic; font-size : 12px;}
		 	
		 	div.sec                    {border : 2px; margin 5px; padding 2px;}
		 	div.title                  {font-family : courier; font-weight : bold;
		 	                            font-size : 16pt; margin : 5px;}
		 	
		 	div.materials_methods      {border-style : double; margin : 5px; }
		 	div.methods                {border-style : double; margin : 5px; }
		 	
		 	div.results                {border-style : solid; margin : 5px;}
		 	div.background             {border-style : dotted; margin : 5px;}
		 	
		 	div.discussion             {border-style : groove; margin : 5px;}
		 	div.conclusion             {border-style : ridge; margin : 5px;}
		 	div.conclusions             {border-style : ridge; margin : 5px;}
		 	div.supplementary-material {border-style : inset; margin : 5px;}
		 	div.abbreviations          {border-style : double; border-color : red; margin : 5px;}
		 	div.competinginterests     {border-style : double; border-color : blue; margin : 5px;}
		 	div.acknowledgements       {border-style : double; border-color : green; margin : 5px;}
		 	div.authors_contributions   {border-style : double; border-color : purple; margin : 5px;}
		 	
		 	div.publisher              {border-style : outset; margin : 5px;}
		 	div.fn-type-conflict       {background : #f88; }
		 	div.fn-type-con            {background : #ddf; }
		 	div.fn-type-other          {background : #ddd; }
		 	
		 	div.unknown                {background : #ffd;
									 	  border-style : solid;
									 	  border-width : 1px;
									 	  padding : 2 px;}
		 	  
      	    table                      {background : #ffffdd;}
		 	tr                         {background : #ddddff; padding : 1px;}
		 	
		 	span                       {background : #ffcccc;}
		 	
		 	span.citation-author       {font-family : helvetica; background : #ffeeee;}
		 	span.collab                {background : #ddffff; }
		 	span.comment               {font-family : courier; font-size : 6px; background : #ffaaff;}
		 	span.contrib               {background : #ffffff;}
		 	span.corresp               {background : #ddffdd; }
		 	span.doi                   {background : #ffffff;}
		 	span.email                 {font-family : courier; }
		 	span.etal                  {font-style : italic;}
		 	span.fpage                 {font-family : courier;}
		 	span.given-names           {background : #ffffff;}
		 	span.iso-abbrev            {background : #ffffff;}
		 	span.issn-epub             {background : #ffffff;}
		 	span.issn-ppub             {background : #ffffff;}
		 	span.journal-title         {background : #ffffff;}
		 	span.lpage                 {font-family : courier;}
		 	span.mixed-article-title   {font-style : italic ;}
		 	span.nlm-ta                {background : #ffffff;}
		 	span.pmc                   {background : #ffffff;}
		 	span.pmcid                 {background : #ffffff;}
		 	span.pmid                  {background : #ffffff;}
		 	span.publisher             {background : #ffffff;}
		 	span.publisher-id          {background : #ffffff;}
		 	span.publisher-name        {background : #ffffff;}
		 	span.source                {background : #ffffff;}
		 	span.subject               {background : #ffffff;}
		 	span.surname               {background : #ffffff;}
		 	span.volume                {font-family : courier; font-weight : bold;}
		 	span.year                  {font-family : courier ; font-style : italic;}
			</style> </head> <body> <div class="front" title="front"> <div class="journal-meta" tagx="journal-meta" title="journal-meta"><span class="nlm-ta" title="nlm-ta">J Enzyme Inhib Med Chem</span><span class="iso-abbrev" title="iso-abbrev">J Enzyme Inhib Med Chem</span><div class="journal-title-group" tagx="journal-title-group" title="journal-title-group"><span class="journal-title" tagx="journal-title" title="journal-title">Journal of Enzyme Inhibition and Medicinal Chemistry</span></div><span class="issn-ppub" tagx="issn" title="issn-ppub">1475-6366</span><span class="issn-epub" tagx="issn" title="issn-epub">1475-6374</span><div class="publisher" tagx="publisher" title="publisher"><span class="publisher-name" tagx="publisher-name" title="publisher-name">Taylor &amp;amp; Francis</span></div> </div> <div class="article-meta" tagx="article-meta" title="article-meta"><span class="pmcid" title="pmcid"> pmcid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/7470104">7470104</a></span><span class="pmid" title="pmid"> pmid: <a href="http://www.ncbi.nlm.nih.gov/pubmed/32781872">32781872</a></span><span class="doi" title="doi"> doi: <a href="https://dx.doi.org/10.1080/14756366.2020.1806259">10.1080/14756366.2020.1806259</a></span><span class="publisher-id" title="publisher-id">1806259</span><div class="unknown" title="article-version" tag="article-version">
Version of Record</div> <div class="article-categories" title="article-categories">
: <span class="subject" title="subject">Research Article</span>: <span class="subject" title="subject">Research Paper</span></div> <div class="title-group" tagx="title-group" title="title-group"> <div class="article-title" title="article-title">
Discovery of 3,6-disubstituted pyridazines as a novel class of anticancer agents targeting cyclin-dependent kinase 2: synthesis, biological evaluation and in silico insights</div> <div class="alt-title" title="alt-title">
A. Sabt et al.</div> </div> <div class="contrib-group" title="contrib-group"><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sabt</span><span class="given-names" tagx="given-names" title="given-names">Ahmed</span></span><a href="#AF0001">a</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">Wagdy M.</span></span><a href="#AF0002">b</a><a href="#AN0001" /></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Warhi</span><span class="given-names" tagx="given-names" title="given-names">Tarfah</span></span><a href="#AF0003">c</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alotaibi</span><span class="given-names" tagx="given-names" title="given-names">Ohoud J.</span></span><a href="#AF0003">c</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elaasser</span><span class="given-names" tagx="given-names" title="given-names">Mahmoud M.</span></span><a href="#AF0004">d</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Suliman</span><span class="given-names" tagx="given-names" title="given-names">Howayda</span></span><a href="#AF0005">e</a></span><span class="contrib" title="contrib"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdel-Aziz</span><span class="given-names" tagx="given-names" title="given-names">Hatem A.</span></span><a href="#AF0006">f</a></span><span class="citation_author_institution" id="AF0001">[a], <span class="institution" title="institution">Chemistry of Natural Compounds Department, National Research Centre</span><span class="city" tagx="city" title="city">Dokki</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0002">[b], <span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University</span><span class="city" tagx="city" title="city">Kafrelsheikh</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0003">[c], <span class="institution" title="institution">Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University</span><span class="city" tagx="city" title="city">Riyadh</span><span class="country" tagx="country" title="country">Saudi Arabia</span></span><span class="citation_author_institution" id="AF0004">[d], <span class="institution" title="institution">The Regional Center for Mycology and Biotechnology, Al-Azhar University</span><span class="city" tagx="city" title="city">Cairo</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0005">[e], <span class="institution" title="institution">Department of Medical Biochemistry, Faculty of Medicine, Alexandria University</span><span class="city" tagx="city" title="city">Alexandria</span><span class="country" tagx="country" title="country">Egypt</span></span><span class="citation_author_institution" id="AF0006">[f], <span class="institution" title="institution">Department of Applied Organic Chemistry, National Research Center</span><span class="city" tagx="city" title="city">Giza</span><span class="country" tagx="country" title="country">Egypt</span></span></div> <div class="author-notes" title="author-notes"> <div class="fn-type-" title=""> <p>Supplemental data for this article can be accessed <u><a href="https://doi.org/10.1080/14756366.2020.1806259">here</a></u>.</p> </div> <div class="corresp" title="corresp"><b>CONTACT</b> Wagdy M. Eldehna <span class="email" tagx="email" title="email">wagdy2000@gmail.com</span><span class="institution" title="institution">Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University</span>, <span class="city" tagx="city" title="city">Kafrelsheikh</span>, <span class="country" tagx="country" title="country">Egypt</span></div> </div><span class="pub-date-" title="pub-date-">: <span>2020-8-8</span></span><span class="pub-date-" title="pub-date-">: <span>2020</span></span><span class="volume" tagx="volume" title="volume">35</span><span class="issue" tagx="issue" title="issue">1</span><span class="fpage" tagx="fpage" title="fpage">1616</span><span class="lpage" tagx="lpage" title="lpage">1630</span><div class="permissions"><span class="copyright" title="copyright">(C) <span class="copyright-holder" tagx="copyright-holder" title="copyright-holder">The Author(s)</span>, <span class="copyright-year" tagx="copyright-year" title="copyright-year">2020</span></span><span class="license" title="license"><span class="license-p" title="license-p">This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<a href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</span></span></div><a class="self-uri" href="IENZ_35_1806259.pdf" title="self-uri">IENZ_35_1806259.pdf</a><div class="abstract" title="abstract"> <div class="abstract-title" title="abstract-title">
Abstract</div> <div class="title" tagx="title" title="title">
Abstract</div> <p>Human health in the current medical era is facing numerous challenges, especially cancer. So, the therapeutic arsenal for cancer should be unremittingly enriched with novel small molecules that selectively target tumour cells with minimal toxicity towards normal cells. In this context, herein a new series of 3,6-disubstituted pyridazines <b>11aâ€"r</b> has been synthesised and evaluated for <i>inÂ vitro</i> anticancer activity. They possessed good anti-proliferative action towards human breast cancer T-47D (IC<sub>50</sub> range: 0.43â€‰Â±â€‰0.01â€‰âˆ’â€‰35.9â€‰Â±â€‰1.18â€‰ÂµM) and MDA-MB-231 (IC<sub>50</sub> range: 0.99â€‰Â±â€‰0.03â€‰âˆ’â€‰34.59â€‰Â±â€‰1.13â€‰ÂµM) cell lines, whereas they displayed weak activity against the tested ovarian cancer cell line SKOV-3. Among the studied compounds, the methyltetrahydropyran-bearing pyridazine <b>11m</b> emerged as the unique submicromolar growth inhibitor herein reported towards both T-47D (IC<sub>50</sub> = 0.43â€‰Â±â€‰0.01â€‰ÂµM) and MDA-MB-231 (IC<sub>50</sub> = 0.99â€‰Â±â€‰0.03â€‰ÂµM) cell lines. In addition, the biological results indicated that pyridazines <b>11l</b> and <b>11m</b> exerted an efficient alteration within the cell cycle progression as well as induction of apoptosis in both T-47D and MDA-MB-231 cells. Moreover, pyridazines <b>11l</b> and <b>11m</b> displayed good mean tumour S. I. values of 13.7 and 16.1 upon assessment of their cytotoxicity towards non-tumorigenic breast MCF-10A cells. Furthermore, an <i>in silico</i> study proposed CDK2 as a probable enzymatic target for pyridazines <b>11</b>, and explored their binding interactions within the vicinity of CDK2 binding site. Subsequently, pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b>, and <b>11m</b> were selected to be evaluated for their ability to inhibit CDK2, where they exerted good inhibitory activity (IC<sub>50</sub> = 151, 43.8, 55.6 and 20.1â€‰nM, respectively). Finally, the <i>in silico</i> study implied that target pyridazines <b>11</b> exhibited not only an efficient anticancer activity but also an acceptable ADME, physicochemical and druglikeness properties, specifically pyridazines <b>11l</b> and <b>11m</b>. Overall the obtained results from this study quite sustained our strategy and gave us a robust opportunity for further development and optimisation of 3,6-disubstituted pyridazine scaffold to enrich therapeutic arsenal with efficient and safe anticancer CDK inhibitors.</p> </div> <div class="kwd-group"> <div class="title" tagx="title" title="title">
Keywords</div> <div class="kwd" title="kwd">
Breast cancer</div> <div class="kwd" title="kwd">
aminopyridazines</div> <div class="kwd" title="kwd">
CDK2 inhibitors</div> <div class="kwd" title="kwd">
apoptosis inducers</div> <div class="kwd" title="kwd">
molecular docking</div> <div class="kwd" title="kwd">
cell cycle arrest</div> </div> <div class="counts" title="counts"><span class="fig-count" title="fig-count">fig-count: </span><span class="table-count" title="table-count">table-count: </span><span class="page-count" title="page-count">page-count: </span><span class="word-count" title="word-count">word-count: </span></div> </div> </div> <div class="body" title="body"> <div class="introduction" title="sec"><span class="label" tagx="label" title="label">1.</span><div class="title" tagx="title" title="title">
Introduction</div> <p>Cancer is a very complex disease, which affects diverse systems and organs within the body. Cancer develops because of the abnormal and uncontrolled cells division, initiated as a result of chemicals, viruses, smoking, or diet. Complications of cancer disease lead to death if left without treatment<a href="#CIT0001"><sup>1</sup></a>. As a serious health problem, mortality due to cancer is expected to surpass that attributable to cardiovascular disorders in a short time. Around seven million cancer-related cases die per year, whereas about more than 26 million new cancer cases and 17 million cancer-related deaths are estimated to be reached per year by 2030<a href="#CIT0002"><sup>2</sup></a>. Accordingly, the therapeutic arsenal for cancer treatment should be urgently enriched with novel small molecules directed towards a certain signalling factor that could be implicated in tumour growth and/or tumorigenesis.</p> <p>Cyclin-dependent kinases (CDKs) are a family of comparatively small proteins, from 34 to 40â€‰kDa, which is classified as serine/threonine protein kinases<a href="#CIT0003"><sup>3</sup></a>. CDKs have essential roles in the cell cycle regulation as well as in apoptosis, transcription and differentiation through binding to a regulatory protein known as â€œcyclinâ€�; only the CDK-cyclin complexes are active kinases<a href="#CIT0004"><sup>4</sup></a><sup>,</sup><a href="#CIT0005"><sup>5</sup></a>.</p> <p>It is well established that excessive production of CDKs, such as CDK1, CDK2, CDK4 and CDK6, or cyclins may result in a disruption of the normal regulation controls and eventually leads to cancer. For this reason, therapeutic approach based on inhibition of CDKs represents an auspicious opportunity and promising strategy for drug discovery and development of novel efficient and targeted chemical entities that can fight different types of human malignancies<a href="#CIT0006"><sup>6</sup></a>. To date, three small molecule CDK inhibitors (palbociclib, abemaciclib and ribociclib) have been approved for clinical use, <a href="#F0001">Figure 1</a><a href="#CIT0007"><sup>7</sup></a>, whereas there are several CDK inhibitors in the clinical trials; such as roniciclib (BAY 1000394, <a href="#F0001">Figure 1</a>)<a href="#CIT0008"><sup>8</sup></a>. However, the side effects and resistance to these inhibitors somehow limits their therapeutic value and discloses the necessity of development of novel CDK inhibitors<a href="#CIT0009"><sup>9</sup></a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 1.</span></a></div>   <p>Chemical structure of the clinically used (palbociclib, abemaciclib and ribociclib) or currently in clinical trials (roniciclib) CDK inhibitors.</p>   </div> <p>Over the last two decades, non-fused pyridazine nucleus has emerged as an important class of heterocycles that represents a promising and privileged scaffold in medicinal chemistry<a href="#CIT0010"><sup>10</sup></a>. Literature survey revealed that plenty of pyridazine-based small molecules have been extensively investigated for a broad array of significant biological actions, such as anti-inflammatory<a href="#CIT0011"><sup>11</sup></a><sup>,</sup><a href="#CIT0012"><sup>12</sup></a>, anti-hypertensive<a href="#CIT0013"><sup>13</sup></a>, anti-diabetic<a href="#CIT0014"><sup>14</sup></a>, anti-obesity<a href="#CIT0015"><sup>15</sup></a>, neuroprotective<a href="#CIT0016"><sup>16</sup></a>, anti-Alzheimerâ€™s<a href="#CIT0017"><sup>17</sup></a>, anti-tubercular<a href="#CIT0018"><sup>18</sup></a>, anti-HIV<a href="#CIT0019"><sup>19</sup></a> and anticancer<a href="#CIT0020"><sup>20</sup></a> activities.</p> <p>While several studies and research work have explored different anticancer activities for diverse fused pyridazine derivatives, little attention has been paid to investigate the anticancer activity for the non-fused 3,6-disubstituted pyridazine derivatives over the last two decades<a href="#CIT0021"><sup>21â€"30</sup></a>. For example; compound <b>I</b> (<a href="#F0002">Figure 2</a>) displayed potent <i>inÂ vitro</i> and <i>inÂ vivo</i> antitumor and anti-angiogenesis activities<a href="#CIT0021"><sup>21</sup></a>, compound <b>II</b> (<a href="#F0002">Figure 2</a>) efficiently inhibited the cell proliferation in a panel of breast, colon, prostate and liver human tumours<a href="#CIT0028"><sup>28</sup></a>. In addition, compound <b>III</b> (<a href="#F0002">Figure 2</a>) elicited excellent cytotoxic activity towards human colon cancer HT-29 cell line<a href="#CIT0022"><sup>22</sup></a>, whereas compound <b>IV</b> (<a href="#F0002">Figure 2</a>) emerged as promising VEGFR-2 inhibitor with IC<sub>50</sub> in the nanomolar range<a href="#CIT0029"><sup>29</sup></a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 2.</span></a></div>   <p>Chemical structure for some 3,6â€�disubstituted pyridazine derivatives reported as efficient anticancer small molecules.</p>   </div> <p>Inspired by the aforementioned findings and as part of our research work on the discovery of efficient anticancer candidates, herein we report in details the synthesis and anticancer activities assessment for a new series of non-fused 3,6-disubstituted pyridazine derivatives <b>11aâ€"r</b> (<a href="#F0002">Figure 2</a>). In this context, the anticancer actions for the 3,6-disubstituted pyridazine derivatives here reported; <b>11aâ€"r</b> will be evaluated against three human cancer cell lines, namely, T-47D and MDA-MB-231 (breast cancers), and SKOV-3 (ovarian cancer) cell lines utilising the protocol of SRB assay. Thereafter, the most potent anti-proliferative pyridazines will be selected to explore their plausible mechanism of action through cell cycle analysis as well as Anx V-FITC apoptosis assay in both breast cancer (T-47D and MDA-MB-231) cell lines. Finally, an <i>in silico</i> study suggested CDK2 as a probable enzymatic target for the herein reported 3,6-disubstituted pyridazines <b>11aâ€"r</b> and explored their binding interactions within the vicinity of CDK2 binding site, thereafter, target pyridazines will be explored for their potential inhibitory activity against CDK2.</p> </div> <div class="resultsanddiscussion" title="sec"><span class="label" tagx="label" title="label">2.</span><div class="title" tagx="title" title="title">
Results and discussion</div> <div class="chemistry" title="sec"><span class="label" tagx="label" title="label">2.1.</span><div class="title" tagx="title" title="title">
Chemistry</div> <p>The target 5-(trifluoromethyl)pyridazine-3-carboxamide derivatives (<b>11aâ€"r</b>) were prepared through several synthetic steps (<a href="#SCH0001 SCH0002 SCH0003">Schemes 1â€"3</a>) starting from the commercially available ethyl 3,3,3-trifluoropyruvate. With respect to <a href="#SCH0001">Scheme 1</a>, ethyl trifluoropyruvate (<b>1</b>) reacted with acetone in the existence of L-proline and DMF following a reported method<a href="#CIT0031"><sup>31</sup></a> to yield ethyl 2-hydroxy-4-oxo-2-(trifluoromethyl)pentanoate (<b>2</b>), the later compound was converted into 6-methyl-4-(trifluoromethyl)pyridazin-3(2H)-one (<b>3</b>) upon reaction with hydrazine hydrate in the existence of acetic acid<a href="#CIT0032"><sup>32</sup></a>. Compound (<b>3</b>) was then subjected to oxidation process using potassium chromate and sulphuric acid at room temperature to give 6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazine-3-carboxylic acid (<b>4</b>). Fischer esterification was then carried out for compound (<b>4</b>) through reflux with ethanol in the presence of sulphuric acid (catalytic amount) in order to afford the corresponding ester derivative (<b>5</b>), <a href="#SCH0001">Scheme 1</a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 1.</span></a></div>   <p>Preparation of ester <b>5</b>; reagents and conditions: (<b>i</b>) Acetone, DMF, L-proline, r.t., 48â€‰h; (<b>ii</b>) NH<sub>2</sub>NH<sub>2</sub>, AcOH, reflux, 6â€‰h; (<b>iii</b>) K<sub>2</sub>Cr<sub>2</sub>O<sub>7</sub>, Conc. H<sub>2</sub>SO<sub>4</sub>, 0â€‰Â°C to r.t. overnight; (<b>iv</b>) EtOH, H<sub>2</sub>SO<sub>4</sub>, reflux, 4â€‰h.</p>   </div> <p>Chlorination of 6-oxo-1,6-dihydropyridazine derivative (<b>5</b>) was performed <i>via</i> its reflux with excess phosphorous oxychloride to furnish ethyl 6-chloro-5-(trifluoromethyl)pyridazine-3-carboxylate (<b>6</b>), which subsequently hydrolysed <i>via</i> treatment with the alkali lithium hydroxide in presence of THF/H<sub>2</sub>O (4/1) then chlorinated with thionyl chloride to afford the crude acid chloride derivative (<b>7</b>). Stirring of acid chloride (<b>7</b>) with the different primary amines <b>8aâ€"e</b> in dichloromethane at r.t. and in the existence of Et<sub>3</sub>N led to formation of the key amide intermediates <b>9aâ€"e</b> (<a href="#SCH0002">Scheme 2</a>).</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 2.</span></a></div>   <p>Preparation of intermediateds <b>9aâ€"e</b>; reagents and conditions: (<b>i</b>) POCl<sub>3</sub>, 100â€‰Â°C, 5â€‰h; (<b>ii</b>) LiOH, THF, H<sub>2</sub>O, r.t., 1â€‰h; (<b>iii</b>) SOCl<sub>2</sub>, DMF (catalytic), 1,2-dichloroethane, reflux, 3â€‰h; (<b>iv</b>) Methylene chloride, Et<sub>3</sub>N, r.t., 4â€‰h.</p>   </div> <p>The target pyridazine derivatives (<b>11aâ€"r</b>) were prepared <i>via</i> two synthetic routes. The first route utilised the key amide intermediates <b>9aâ€"e</b>, which reacted with the amines <b>8a</b>, <b>8e</b> and <b>10aâ€"d</b> in refluxing 1,4-dioxane in the presence of HÃ¼nigâ€™s base in order to furnish target pyridazines <b>11aâ€"r</b> (<a href="#SCH0003">Scheme 3</a>). This synthetic pathway proved successful to prepare target pyridazines <b>11aâ€"r</b> with low to good yields; 36â€"79%. In the second route, ethyl 6-chloro-5-(trifluoromethyl)pyridazine-3-carboxylate (<b>6</b>) was subjected to a nucleophilic substitution with morpholine in boiling 1,4-dioxane in the existence of HÃ¼nigâ€™s base to furnish ethyl 6-morpholino-5-(trifluoromethyl)pyridazine-3-carboxylate (<b>13</b>), which subsequently underwent direct amidation that accomplished <i>via</i> reaction with primary amines <b>8aâ€"e</b> in absolute ethyl alcohol in the existence of piperidine to yield the corresponding target pyridazines <b>11d</b>, <b>11g</b>, <b>11i</b>, <b>11m</b> and <b>11r</b>, respectively, with overall 29â€"54% yield for the two steps; nucleophilic substitution and direct amidation (<a href="#SCH0003">Scheme 3</a>)<a href="#CIT0033"><sup>33</sup></a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Scheme 3.</span></a></div>   <p>Preparation of target pyridazines <b>11aâ€"r</b>; reagents and conditions: (<b>i</b>) 1,4-Dioxane, HÃ¼nigâ€™s base, reflux, 6â€‰h; (<b>ii</b>) Morpholine, 1,4-dioxane, HÃ¼nigâ€™s base, reflux, 12â€‰h; (<b>iii</b>) Primary amines <b>8aâ€"e</b>, EtOH, piperdine, reflux, 6â€‰h.</p>   </div> <p>It is worth emphasising that pyridazines <b>11d</b>, <b>11g</b>, <b>11i</b>, <b>11m</b> and <b>11r</b> were also prepared utilising the first route, from the key amide intermediates <b>9aâ€"e</b>, with higher yields (50â€"73%) than those afforded from the second route (29â€"54%), suggesting first route as more advantageous to synthesise final target pyridazines.</p> </div> <div class="biologicalevaluation" title="sec"><span class="label" tagx="label" title="label">2.2.</span><div class="title" tagx="title" title="title">
Biological evaluation</div> <div class="invitroanti-proliferativeactivities" title="sec"><span class="label" tagx="label" title="label">2.2.1.</span><div class="title" tagx="title" title="title"><i>In vitro</i> anti-proliferative activities</div> <p>The newly herein reported pyridazines <b>11aâ€"r</b> were assessed for their anti-proliferative potential towards three human cancer cell lines, namely, T-47D (breast cancer), MDA-MB-231 (breast cancer) and SKOV-3 (ovarian cancer) cell lines by using the protocol of the SRB assay<a href="#CIT0034"><sup>34</sup></a>. MDA-MB-231 cell line is classified as a triple-negative/basal-like cell line, which is hormone (estrogen and progesterone)-receptor negative and HER2 negative, whereas T-47D is considered as hormone-receptor positive and HER2 negative breast cancer cell line. The IC<sub>50</sub> values for target pyridazines <b>11aâ€"r</b> were determined, and were represented in <a href="#t0001">Table 1</a>.</p> <div class="table-wrap_UNKNOWN" id="t0001" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 1.</span> <p>Anti-proliferative activities for the newly prepared pyridazines (<b>11aâ€"r</b>) towards T-47D, MDA-MB-231 and SKOV-3 cell lines. </p>  <table frame="hsides" rules="groups"> <colgroup> <col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup>  <tbody valign="top"> <tr> <td colspan="6" align="center"><span class="inline-graphic" title="inline-graphic" /></td> </tr> <tr> <td colspan="6" align="center"><span class="inline-graphic" title="inline-graphic" /></td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p><sup>a</sup>IC<sub>50</sub>s are displayed as meanâ€‰Â±â€‰SD for three separate experiments.</p> </div> <div class="fn-type-" title=""> <p><sup>b</sup>NA: Pyridazines with IC<sub>50</sub> value more than 100â€‰ÂµM.</p> </div> </div> </div> <p>The obtained results disclosed that all the screened pyridazines possessed excellent to moderate anticancer action against the two tested breast cancer (T-47D and MDA-MB-231) cell lines, whereas they displayed weak to non-significant cytotoxic impact against the tested ovarian cancer (SKOV-3) cell line, <a href="#t0001">Table 1</a>. Nonetheless, it was noted that the screened pyridazines <b>11aâ€"r</b> exhibited differential activities against the two tested human breast cancer cell lines; 8 out of 18 compounds were more active against T-47D than MDA-MB-231, whereas 10 out of 18 compounds were more active against MDA-MB-231 than T-47D as indicated in <a href="#t0001">Table 1</a>. In details, T-47D cells were more sensitive (IC<sub>50</sub> range 0.44â€‰Â±â€‰0.01â€‰âˆ’â€‰11.44â€‰Â±â€‰0.37â€‰ÂµM) to the influence of all 2-adamantyl-bearing pyridazines <b>11aâ€"e</b> (except <b>11d</b>), <i>tert</i>-butyl-bearing pyridazines <b>11fâ€"h</b> (except <b>11â€‰g</b>) and butyl-bearing pyridazine (<b>11i</b>) than MDA-MB-231 cells (IC<sub>50</sub> range 2.18â€‰Â±â€‰0.07â€‰âˆ’â€‰34.59â€‰Â±â€‰1.13â€‰ÂµM), <a href="#t0001">Table 1</a>. On the contrary, the methyltetrahydropyran-bearing pyridazines <b>11jâ€"l</b> and 2-(trifluoromethyl)benzyl-bearing pyridazines <b>11nâ€"r</b> displayed better cytotoxic activity against MDA-MB-231 (IC<sub>50</sub> range 1.30â€‰Â±â€‰0.04â€‰âˆ’â€‰19.71â€‰Â±â€‰0.64â€‰ÂµM) than T-47D cell line (IC<sub>50</sub> range 1.57â€‰Â±â€‰0.05â€‰âˆ’â€‰35.9â€‰Â±â€‰1.18â€‰ÂµM).</p> <p>Concerning the anti-proliferative activity of target pyridazines <b>11aâ€"r</b> against breast cancer T-47D cell line, the results indicated that the growth of the T-47D cells was effectively inhibited by all pyridazines reported here with IC<sub>50</sub>s spanned in the range 0.43â€‰Â±â€‰0.01â€‰âˆ’â€‰15.76â€‰Â±â€‰0.51â€‰ÂµM, except for <b>11j</b> and <b>11r</b> which weakly inhibited the T-47D growth (IC<sub>50</sub> = 35.9â€‰Â±â€‰1.18 and 24.80â€‰Â±â€‰0.81â€‰ÂµM, respectively). Outstandingly, two pyridazines displayed submicromolar potency against T-47D cells were identified, that were the butyl-bearing pyridazine (<b>11i</b>) and methyltetrahydropyran-bearing pyridazine (<b>11m</b>), whose IC<sub>50</sub>s of 0.44â€‰Â±â€‰0.01 and 0.43â€‰Â±â€‰0.01â€‰ÂµM represent the best growth inhibition here reported for T-47D cells (<a href="#t0001">Table 1</a>). Interestingly, both pyridazines <b>11i</b> and <b>11m</b> are decorated with morpholine moiety at C-6 position. Moreover, pyridazines <b>11b</b>, <b>11e</b>, <b>11f</b>, <b>11h</b> and <b>11l</b> showed excellent cytotoxic activity against pyridazines <b>11m</b> T-47D cell line with IC<sub>50</sub> values equal 1.37â€‰Â±â€‰0.04, 2.62â€‰Â±â€‰0.08, 1.94â€‰Â±â€‰0.06, 1.60â€‰Â±â€‰0.05 and 1.57â€‰Â±â€‰0.05â€‰ÂµM, respectively.</p> <p>With respect to the anticancer activity against MDA-MB-231 cells, the obtained growth inhibitory data (<a href="#t0001">Table 1</a>) ascribed to most newly synthesised pyridazines <b>11</b> good efficacy in inhibiting the growth of MDA-MB-231 cells, with IC<sub>50</sub>s ranging between 0.99â€‰Â±â€‰0.03 and 19.71â€‰Â±â€‰0.64â€‰ÂµM. Uniquely, compound <b>11a</b> induced weak growth inhibition towards MDA-MB-231 cell line with IC<sub>50</sub> equals 34.59â€‰Â±â€‰1.13â€‰ÂµM (<a href="#t0001">Table 1</a>). It is worth stressing that methyltetrahydropyran-bearing pyridazine (<b>11m</b>) superiorly displayed submicromolar potency towards MDA-MB-231 cell line (IC<sub>50</sub> = 0.99â€‰Â±â€‰0.03â€‰ÂµM), and thus <b>11m</b> emerged as the unique submicromolar growth inhibitor herein reported towards both breast cancer T-47D and MDA-MB-231 cell lines. In addition, pyridazines <b>11d</b>, <b>11h</b>, <b>11l</b> and <b>11n</b> elicited excellent growth inhibitory action towards MDA-MB-231 cell lines with IC<sub>50</sub> values of 2.18â€‰Â±â€‰0.07, 2.44â€‰Â±â€‰0.08, 1.30â€‰Â±â€‰0.04 and 2.94â€‰Â±â€‰0.09â€‰ÂµM, respectively (<a href="#t0001">Table 1</a>).</p> <p>On the other hand, the cytotoxic action for pyridazines <b>11l</b> and <b>11m</b>, the most potent anti-proliferative agents with dual growth inhibitory activities towards T-47D and MDA-MB-231, against non-tumorigenic human breast (MCF-10A) cells has been assessed by the use of the MTT assay in order to explore the selectivity and safety for target pyridazines reported here towards the non-tumorigenic normal cells. The obtained IC<sub>50</sub> values were displayed in <a href="#t0002">Table 2</a>, in addition to the calculated mean tumour selectivity index (S. I.); IC<sub>50</sub> for MCF-10A/ IC<sub>50</sub> average for (T-47D and MDA-MB-231). As results indicated, examined pyridazines <b>11l</b> and <b>11m</b> displayed good mean tumour S. I. values of 13.7 and 16.1, respectively, which discloses good safety profile for target pyridazines as antitumor agents.</p> <div class="table-wrap_UNKNOWN" id="t0002" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 2.</span> <p>Cytotoxic impact for pyridazines <b>11l</b> and <b>11m</b> against non-tumorigenic MCF-10A human breast cell line, as well as mean tumour selectivity index (S. I.) (MCF-10A/T-47D and MDA-MB-231).</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup>  <thead> <tr> <th rowspan="2" align="left">Comp.</th> <th colspan="3" align="center">IC<sub>50</sub> (ÂµM) <hr /> </th> <th rowspan="2" align="center">Mean tumour selectivity</th> </tr> <tr> <th align="center">MCF-10A</th> <th align="center">T-47D</th> <th align="center">MDA-MB-231</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>11l</b></td> <td align="char" char=".">19.63â€‰Â±â€‰0.38</td> <td align="char" char=".">1.57â€‰Â±â€‰0.05</td> <td align="char" char=".">1.30â€‰Â±â€‰0.04</td> <td align="char" char=".">13.7</td> </tr> <tr> <td align="left"><b>11m</b></td> <td align="char" char=".">11.44â€‰Â±â€‰0.22</td> <td align="char" char=".">0.43â€‰Â±â€‰0.01</td> <td align="char" char=".">0.99â€‰Â±â€‰0.03</td> <td align="char" char=".">16.1</td> </tr> </tbody> </table> </div> </div> <div class="cellcycleanalysis" title="sec"><span class="label" tagx="label" title="label">2.2.2.</span><div class="title" tagx="title" title="title">
Cell cycle analysis</div> <p>In this study, the efficient anti-proliferative activities of target pyridazines <b>11</b>a-r towards breast cancer cell lines promoted us to explore and get insights into the plausible cellular mechanisms for these small molecules. To this end, we decided to determine if the target pyridazines exerted their cytotoxic activity through alteration in cell cycle progression and/or induction of apoptosis in both breast cancer T-47D and MDA-MB-231 cells. As a reliable tool, the flow cytometric analysis was utilised to inspect the cell cycle distribution after treatment of T-47D and MDA-MB-231 cells with IC<sub>50</sub>s of pyridazines <b>11l</b> and <b>11m</b>; the most potent cytotoxic agents towards both examined breast cancer cell lines (<a href="#t0001">Table 1</a>).</p> <p>As results indicated, pyridazines <b>11l</b> and <b>11m</b> were able to provoke a significant rise in the cellular population of the G2/M phase in T-47D cells by 2.7- and 2.5-fold, respectively, with concurrent significant increase in the sub-G1 phase by 13.8- and 9.5-fold, respectively, <a href="#F0003">Figure 3(A)</a>. In addition, treatment of MDA-MB-231 cells by pyridazines <b>11l</b> and <b>11m</b> elicited a significant increase in the cell population within both G2/M phase (by 4.1 and 3.8-fold, respectively) and sub-G1 phase (by 18.9- and 15.2-fold, respectively) with respect to untreated control cells (<a href="#F0003">Figure 3(B)</a>). Conclusively, both alteration of the Sub-G<sub>1</sub> phase as well as arrest of G<sub>2</sub>-M phase are featured as significant remarks for pyridazines <b>11l</b> and <b>11m</b> to trigger apoptosis in T-47D and MDA-MB-231 cancer cells.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 3.</span></a></div>   <p>Influence of pyridazines <b>11l</b> and <b>11â€‰m</b> on the distribution of cell cycle phases in breast cancer T-47D (<b>A</b>) and MDA-MB-231 (<b>B</b>) cells. Asterisk indicates a significant difference from control at <i>p</i>â€‰<div class="â€‰0.05._UNKNOWN" /></p>   </div> </div> <div class="annexinv-fitcapoptosisassay" title="sec"><span class="label" tagx="label" title="label">2.2.3.</span><div class="title" tagx="title" title="title">
Annexin V-FITC apoptosis assay</div> <p>In this study, the apoptotic potential for pyridazines <b>11l</b> and <b>11m</b>, the most potent anti-proliferative agents herein reported, has been assessed in both breast cancer T-47D and MDA-MB-231 cell lines using Annexin V FITC/PI dual staining assay. Both T-47D and MDA-MB-231 cells were treated with pyridazines <b>11l</b> and <b>11m</b> at their IC<sub>50</sub>s for 48â€‰h. The obtained results have been depicted in <a href="#F0004 F0005 F0006">Figures 4â€"6</a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 4.</span></a></div>   <p>Percentage of apoptotic and necrotic cells in T-47D (<b>A</b>) and MDA-MB-231 (<b>B</b>), with respect to untreated control cells, upon treatment with pyridazines <b>11l</b> and <b>11m</b>.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 5.</span></a></div>   <p>Influence of pyridazines <b>11l</b> and <b>11m</b> on the percentage of Annexin V<sup>+</sup> apoptotic cells in T-47D cells.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 6.</span></a></div>   <p>Influence of pyridazines <b>11l</b> and <b>11m</b> on the percentage of Annexin V<sup>+</sup> apoptotic cells in MDA-MB-231 cells.</p>   </div> <p>The outcomes from the flow cytometric analysis revealed that T-47D cells treated with pyridazines <b>11l</b> and <b>11m</b> exhibited a significant rise in the percent of Anx V-FITC positive (Annexin V<sup>+</sup>) apoptotic cells within both early (from 0.81% to 6.39% and 11.36%, respectively) and late (from 0.19% to 27.2% and 10.34%, respectively) apoptotic phases (URâ€‰+â€‰LR), which involves about 33- and 21-fold increase with respect to untreated control cells (<a href="#F0004">Figures 4(A)</a> and <a href="#F0005">5</a>).</p> <p>On the other hand, the flow cytometric analysis disclosed that the apoptotic rates (Annexin V<sup>+</sup>) of MDA-MB-231 cells were significantly increased from 0.56% for untreated control cells to 3.38% and 8.19%, respectively, in the early apoptotic phase, as well as from 0.24% for untreated control cells to 23.60% and 15.56%, respectively, in the late apoptotic phase; after treatment of MDA-MB-231 cells with the IC<sub>50</sub>s of pyridazines <b>11l</b> and <b>11m</b> (<a href="#F0004">Figures 4(B)</a> and <a href="#F0006">6</a>).</p> </div> </div> <div class="insilicotargetprediction" title="sec"><span class="label" tagx="label" title="label">2.3.</span><div class="title" tagx="title" title="title">
In silico target prediction</div> <p>Swiss Target Prediction is an online tool that created in 2014 in order to predict the potential targets for any small molecule<a href="#CIT0035"><sup>35</sup></a>. This tool can deduce the best potential macromolecular targets for the small molecules, assumed as bioactives. The predictions are based on 2D and 3D similarity combination with a library includes more than 370â€™000 known actives towards more than three thousands proteins from 3 different species<a href="#CIT0036"><sup>36</sup></a>. In this study we utilised the online SwissTargetPrediction tool to explore the potential enzymatic targets for the herein reported pyridazine derivatives.</p> <p>The generated prediction results, for two representative compounds <b>11a</b> and <b>11j</b>, suggested the protein kinases as the most probable targets (Supporting materials). In particular, CDK2 is listed as one of the top suggested kinases. It is interesting to note that the suggestion of CDK2 as a potential target is perfectly tuned with its known expression in breast cancer<a href="#CIT0037"><sup>37</sup></a>, and with the obtained results from the cell cycle analysis, as the role of CDK2 in the cell cycle is well-established<a href="#CIT0003"><sup>3</sup></a>. Accordingly, a molecular docking work was conducted in order to examine the plausible binding modes and interactions of the target pyridazines <b>11aâ€"r</b> within the active site of CDK2.</p> </div> <div class="cdk2inhibitoryactivity" title="sec"><span class="label" tagx="label" title="label">2.4.</span><div class="title" tagx="title" title="title">
Cdk2 inhibitory activity</div> <div class="moleculardocking" title="sec"><span class="label" tagx="label" title="label">2.4.1.</span><div class="title" tagx="title" title="title">
Molecular docking</div> <p>Molecular docking is among the most utilised drug design techniques that provide insights on how ligands could bind to their targets and the efficiency of theses ligands by scoring them on basis of energy and interactions. Based on suggestion of SwissTargetPrediction tool that CDK2 kinase could be a potential target for the synthesised pyridazines, docking was used to validate this assumption and also to select the most promising analogues for a further biological screening.</p> <p>Initially, the protocol of the molecular docking has been validated <i>via</i> redocking of the co-crystalized ligand Roniciclib within the vicinity of CDK2 binding site. The performed redocking procedure re-produced the original binding manner for the co-crystallized Roniciclib quite adequately implying the convenience of the utilised steps for the desired docking analysis. This was evidenced by the small RMSD of 0.53â€‰Ã… between the co-crystallized Roniciclib and the docked pose (energy score (<i>S</i>) = âˆ’9.2â€‰kcal/mol), as well as by the reproducing of all interactions accomplished by the co-crystallized Roniciclib within the CDK2 active site.</p> <p>Generally, all the target pyridazines <b>11aâ€"r</b> achieved acceptable binding interactions and energy scores. In particular, compounds <b>11m</b>, <b>11e</b>, <b>11h</b> and <b>11l</b> achieved the highest scores (âˆ’10.2, âˆ’10.1, âˆ’9.5 and âˆ’9.0â€‰Kcal\mole, respectively, <a href="#t0003">Table 3</a>). The four compounds (<b>11e</b>, <b>11h</b>, <b>11l</b>, and <b>11m</b>) have successfully bound strongly to the CDK2 active site; forming different types of interaction including hydrophobic interactions with non-polar residues (such as Ala31, Val18, Val64, Phe80, Ala144, Phe82 and Leu134), as well as hydrogen bonding with other residues (such as Asp86, Leu83 and Lys89), <a href="#F0007 F0008 F0009 F0010">Figures 7â€"10</a>. All the bonding interactions within CDK2 active site for pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b>, and <b>11m</b> were outlined in <a href="#t0004">Table 4</a>. The obtained results from the docking study supported the assumption generated from the SwissTargetPrediction server and directed us to conduct a biological evaluation for the best energy scoring pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b>, and <b>11m</b> against CDK2 enzyme.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 7.</span></a></div>   <p>(A) 2D, and (B) 3D diagram for pyridazine <b>11e</b> demonstrating its interactions within the CDK2 active site.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 8.</span></a></div>   <p>(A) 2D, and (B) 3D diagram for pyridazine <b>11h</b> demonstrating its interactions within the CDK2 active site.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 9.</span></a></div>   <p>(A) 2D, and (B) 3D diagram for pyridazine <b>11l</b> demonstrating its interactions within the CDK2 active site.</p>   </div> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 10.</span></a></div>   <p>(A) 2D, and (B) 3D diagram for pyridazine <b>11m</b> demonstrating its interactions within the CDK2 active site.</p>   </div> <div class="table-wrap_UNKNOWN" id="t0003" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 3.</span> <p>Docking energy scores (<i>S</i>) for pyridazines <b>11aâ€"r</b> and the co-crystallized ligand Roniciclib (in in kcal/mol).</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup>  <thead> <tr> <th align="left">Cpd.</th> <th align="center">Energy score (<i>S</i>) Kcal\mole</th> <th align="center">Cpd.</th> <th align="center">Energy score (<i>S</i>) Kcal\mole</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>11a</b></td> <td align="char" char=".">âˆ’8.1</td> <td align="left"><b>11j</b></td> <td align="char" char=".">âˆ’8.3</td> </tr> <tr> <td align="left"><b>11b</b></td> <td align="char" char=".">âˆ’8.0</td> <td align="left"><b>11k</b></td> <td align="char" char=".">âˆ’8.7</td> </tr> <tr> <td align="left"><b>11c</b></td> <td align="char" char=".">âˆ’8.2</td> <td align="left"><b>11l</b></td> <td align="char" char="."><b>âˆ’9.5</b></td> </tr> <tr> <td align="left"><b>11d</b></td> <td align="char" char=".">âˆ’7.9</td> <td align="left"><b>11m</b></td> <td align="char" char="."><b>âˆ’10.2</b></td> </tr> <tr> <td align="left"><b>11e</b></td> <td align="char" char="."><b>âˆ’9.0</b></td> <td align="left"><b>11n</b></td> <td align="char" char=".">âˆ’8.6</td> </tr> <tr> <td align="left"><b>11f</b></td> <td align="char" char=".">âˆ’8.3</td> <td align="left"><b>11o</b></td> <td align="char" char=".">âˆ’8.0</td> </tr> <tr> <td align="left"><b>11g</b></td> <td align="char" char=".">âˆ’7.9</td> <td align="left"><b>11p</b></td> <td align="char" char=".">âˆ’8.7</td> </tr> <tr> <td align="left"><b>11h</b></td> <td align="char" char="."><b>âˆ’10.1</b></td> <td align="left"><b>11q</b></td> <td align="char" char=".">âˆ’8.2</td> </tr> <tr> <td align="left"><b>11i</b></td> <td align="char" char=".">âˆ’8.5</td> <td align="left"><b>11r</b></td> <td align="char" char=".">âˆ’8.4</td> </tr> <tr> <td align="left"><b>Roniciclib</b></td> <td align="char" char=".">âˆ’9.2</td> <td align="left">Â </td> <td align="char" char=".">Â </td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>Bold values are for pyridazines with best docking energy scores.</p> </div> </div> </div> <div class="table-wrap_UNKNOWN" id="t0004" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 4.</span> <p>The different bonding types and their distances (in Ã…) for pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b>, and <b>11m</b> within the CDK2 active site.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup>  <thead> <tr> <th align="left">Cpd</th> <th align="center">Bond type (Involved A. A.)</th> <th align="center">Distance</th> <th align="center">Cpd</th> <th align="center">Bond type (Involved A. A.)</th> <th align="center">Distance</th> </tr> </thead> <tbody valign="top"> <tr> <td><b>11e</b></td> <td>Hydrogen bond (Lys33)</td> <td align="char" char=".">2.69</td> <td><b>11l</b></td> <td>Hydrogen bond (Leu83)</td> <td align="char" char=".">2.61</td> </tr> <tr> <td>Â </td> <td>Hydrogen bond (Lys33)</td> <td align="char" char=".">2.81</td> <td>Â </td> <td>Halogen interaction (Leu83)</td> <td align="char" char=".">3.39</td> </tr> <tr> <td>Â </td> <td>Halogen interaction (Asp145)</td> <td align="char" char=".">3.31</td> <td>Â </td> <td>Halogen interaction (His84)</td> <td align="char" char=".">3.14</td> </tr> <tr> <td>Â </td> <td>Halogen interaction (Asp145)</td> <td align="char" char=".">3.35</td> <td>Â </td> <td>Halogen interaction (His84)</td> <td align="char" char=".">3.02</td> </tr> <tr> <td>Â </td> <td>Halogen interaction (Gly13)</td> <td align="char" char=".">2.39</td> <td>Â </td> <td>Pi-Alkyl (Ile10)</td> <td align="char" char=".">4.35</td> </tr> <tr> <td>Â </td> <td>Halogen interaction (Gly16)</td> <td align="char" char=".">3.62</td> <td>Â </td> <td>Non-classical hydrogen bond (Ile10)</td> <td align="char" char=".">3.60</td> </tr> <tr> <td>Â </td> <td>Halogen interaction (Glu12)</td> <td align="char" char=".">3.26</td> <td>Â </td> <td>Ionic bond (Asp86)</td> <td align="char" char=".">3.37</td> </tr> <tr> <td>Â </td> <td>Pi-Anion (Asp145)</td> <td align="char" char=".">3.65</td> <td>Â </td> <td>Pi-Alkyl (Leu134)</td> <td align="char" char=".">5.13</td> </tr> <tr> <td>Â </td> <td>Pi-Alkyl (Leu134)</td> <td align="char" char=".">4.57</td> <td>Â </td> <td>Pi-Alkyl (Phe80)</td> <td align="char" char=".">4.53</td> </tr> <tr> <td>Â </td> <td>Alkyl-Alkyl (Leu134)</td> <td align="char" char=".">4.64</td> <td>Â </td> <td>Alkyl-Alkyl (Val18)</td> <td align="char" char=".">4.92</td> </tr> <tr> <td>Â </td> <td>Alkyl-Alkyl (Val18)</td> <td align="char" char=".">4.99</td> <td>Â </td> <td>Alkyl-Alkyl (Val64)</td> <td align="char" char=".">5.26</td> </tr> <tr> <td>Â </td> <td>Alkyl-Alkyl (Val18)</td> <td align="char" char=".">4.59</td> <td>Â </td> <td>Alkyl-Alkyl (Ala144)</td> <td align="char" char=".">4.08</td> </tr> <tr> <td>Â </td> <td>Pi-Alkyl (Ile10)</td> <td align="char" char=".">5.02</td> <td>Â </td> <td>Alkyl-Alkyl (Lys33)</td> <td align="char" char=".">5.37</td> </tr> <tr> <td>Â </td> <td>Alkyl-Alkyl (Lys89)</td> <td align="char" char=".">5.37</td> <td>Â </td> <td>Non-classical hydrogen bond (Gln85)</td> <td align="char" char=".">2.25</td> </tr> <tr> <td>Â </td> <td>Alkyl-Alkyl (Lys89)</td> <td align="char" char=".">5.48</td> <td>Â </td> <td>Â </td> <td>Â </td> </tr> <tr> <td>Â </td> <td>Alkyl-Alkyl (Lys89)</td> <td align="char" char=".">5.49</td> <td>Â </td> <td>Â </td> <td>Â </td> </tr> <tr> <td><b>11h</b></td> <td>Hydrogen bond (Asp86)</td> <td align="char" char=".">2.13</td> <td><b>11m</b></td> <td>Hydrogen bond (Leu83)</td> <td align="char" char=".">2.02</td> </tr> <tr> <td>Â </td> <td>Hydrogen bond (Leu83)</td> <td align="char" char=".">2.59</td> <td>Â </td> <td>Alkyl-Alkyl (Lys89)</td> <td align="char" char=".">5.34</td> </tr> <tr> <td>Â </td> <td>Halogen interaction (Asp145)</td> <td align="char" char=".">3.15</td> <td>Â </td> <td>Halogen interaction (Ile10)</td> <td align="char" char=".">2.94</td> </tr> <tr> <td>Â </td> <td>Halogen interaction (Asp145)</td> <td align="char" char=".">3.19</td> <td>Â </td> <td>Halogen interaction (Ile10)</td> <td align="char" char=".">3.10</td> </tr> <tr> <td>Â </td> <td>Halogen interaction (Asn132)</td> <td align="char" char=".">3.14</td> <td>Â </td> <td>Halogen interaction (Asp86)</td> <td align="char" char=".">3.00</td> </tr> <tr> <td>Â </td> <td>Halogen interaction (Leu83)</td> <td align="char" char=".">2.86</td> <td>Â </td> <td>Halogen interaction (Asp86)</td> <td align="char" char=".">3.27</td> </tr> <tr> <td>Â </td> <td>Halogen interaction (Leu83)</td> <td align="char" char=".">3.17</td> <td>Â </td> <td>Halogen interaction (Gln131)</td> <td align="char" char=".">2.80</td> </tr> <tr> <td>Â </td> <td>Pi-Alkyl (Ile10)</td> <td align="char" char=".">4.30</td> <td>Â </td> <td>Pi-Alkyl (Ile10)</td> <td align="char" char=".">3.94</td> </tr> <tr> <td>Â </td> <td>Alkyl-Alkyl (Ile10)</td> <td align="char" char=".">4.71</td> <td>Â </td> <td>Alkyl-Alkyl (Ile10)</td> <td align="char" char=".">5.42</td> </tr> <tr> <td>Â </td> <td>Pi-Alkyl (Leu134)</td> <td align="char" char=".">5.04</td> <td>Â </td> <td>Non-classical hydrogen bond (Ile10)</td> <td align="char" char=".">3.48</td> </tr> <tr> <td>Â </td> <td>Alkyl-Alkyl (Leu134)</td> <td align="char" char=".">4.37</td> <td>Â </td> <td>Alkyl-Alkyl (Lys33)</td> <td align="char" char=".">5.28</td> </tr> <tr> <td>Â </td> <td>Pi-Alkyl (Phe82)</td> <td align="char" char=".">5.02</td> <td>Â </td> <td>Non-classical hydrogen bond (Phe82)</td> <td align="char" char=".">2.66</td> </tr> <tr> <td>Â </td> <td>Pi-Alkyl (Val18)</td> <td align="char" char=".">4.76</td> <td>Â </td> <td>Non-classical hydrogen bond (Glu81)</td> <td align="char" char=".">3.74</td> </tr> <tr> <td>Â </td> <td>Alkyl-Alkyl (Val18)</td> <td align="char" char=".">4.43</td> <td>Â </td> <td>Pi-Sigma interaction (Phe80)</td> <td align="char" char=".">3.50</td> </tr> <tr> <td>Â </td> <td>Pi-Alkyl (Ala144)</td> <td align="char" char=".">3.97</td> <td>Â </td> <td>Alkyl-Alkyl (Val18)</td> <td align="char" char=".">5.02</td> </tr> <tr> <td>Â </td> <td>Pi-Pi interaction (Phe80)</td> <td align="char" char=".">5.14</td> <td>Â </td> <td>Alkyl-Alkyl (Val64)</td> <td align="char" char=".">5.03</td> </tr> <tr> <td>Â </td> <td>Non-classical hydrogen bond (Lys33)</td> <td align="char" char=".">2.79</td> <td>Â </td> <td>Alkyl-Alkyl (Ala144)</td> <td align="char" char=".">4.29</td> </tr> <tr> <td>Â </td> <td>Â </td> <td>Â </td> <td>Â </td> <td>Alkyl-Alkyl (Ala31)</td> <td align="char" char=".">5.00</td> </tr> <tr> <td>Â </td> <td>Â </td> <td>Â </td> <td>Â </td> <td>Pi-Alkyl interaction (Leu134)</td> <td align="char" char=".">4.96</td> </tr> </tbody> </table> </div> </div> <div class="invitrocdk2kinaseassay" title="sec"><span class="label" tagx="label" title="label">2.4.2.</span><div class="title" tagx="title" title="title"><i>In vitro</i> CDK2 kinase assay</div> <p>On account of their best scores achieved in the docking study (<a href="#t0003">Table 3</a>) as well as their efficient anti-proliferative actions towards both the examined breast cancer cell lines (<a href="#t0001">Table 1</a>), pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b>, and <b>11m</b> were selected to be examined for their ability to inhibit CDK2. The results have been obtained as IC<sub>50</sub> values which listed in <a href="#t0005">Table 5</a>.</p> <div class="table-wrap_UNKNOWN" id="t0005" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 5.</span> <p>IC<sub>50</sub> values for the CDK2 inhibitory action of pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b>, and <b>11m</b>.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup>  <thead> <tr> <th rowspan="2" align="left">Comp.</th> <th align="center">IC<sub>50</sub> (nM)</th> </tr> <tr> <th align="center">CDK2</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>11e</b></td> <td align="left">151â€‰Â±â€‰6.16</td> </tr> <tr> <td align="left"><b>11h</b></td> <td align="left">43.8â€‰Â±â€‰1.79</td> </tr> <tr> <td align="left"><b>11l</b></td> <td align="left">55.6â€‰Â±â€‰2.27</td> </tr> <tr> <td align="left"><b>11m</b></td> <td align="left">20.1â€‰Â±â€‰0.82</td> </tr> <tr> <td align="left"><b>Staurosporine</b></td> <td align="left">12.4â€‰Â±â€‰0.51</td> </tr> </tbody> </table> </div> <p>The results revealed that the examined pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b>, and <b>11m</b> possessed good inhibitory action towards CDK2 kinase with IC<sub>50</sub> values equal 151â€‰Â±â€‰6.16, 43.8â€‰Â±â€‰1.79, 55.6â€‰Â±â€‰2.27 and 20.1â€‰Â±â€‰0.82â€‰nM, respectively (<a href="#t0005">Table 5</a>). Remarkably pyridazine derivative <b>11m</b>, bearing two morpholine moieties, elicited the best CDK2 inhibitory activity in this study (IC<sub>50</sub> = 20.1â€‰Â±â€‰0.82â€‰nM), alongside to its superior anti-proliferative activity that has been reported above (<a href="#t0001">Table 1</a>). Itâ€™s worth stressing that this is the first study, to the best of our knowledge, that reports on 3,6-disubstituted pyridazines as anticancer CDK inhibitors.</p> </div> </div> <div class="insilicoadmecalculation" title="sec"><span class="label" tagx="label" title="label">2.5.</span><div class="title" tagx="title" title="title">
In silico ADME calculation</div> <p>As a rule, novel small molecules considered as potential drug candidates when they possess acceptable pharmacokinetic and pharmacodynamic profiles. Thus, assessment of the efficiency for the synthesised compounds should rely not only on basis of their biological activities but also with taking in consideration their pharmacokinetics, druglikness and physicochemical properties.</p> <p>The SwissADME online tool has been adopted to calculate the ADME profiles for target pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b> and <b>11m</b><a href="#CIT0038"><sup>38</sup></a>. Target pyridazines <b>11h</b>, <b>11l</b> and <b>11m</b> were predicted to have high gastrointestinal tract (GIT) absorption, as they were present within the region of human intestinal absorption (HIA) in the BOILED-Egg chart<a href="#CIT0039"><sup>39</sup></a>, whereas compound <b>11e</b> was located outside the region of HIA in the BOILED-Egg chart (<a href="#F0011">Figure 11</a>) and thus predicted to possess low GIT absorption that may hinder its oral bioavailability. The low GIT absorption predicted for compound <b>11e</b> could be attributed to the pronounced lipophilicity of the rigid polycyclic cage hydrocarbon adamantine, as well as incorporation of <i>ortho</i>-trifluoromethyl phenyl moiety. At the same time, the BOILED-Egg graph (<a href="#F0011">Figure 11</a>) pointed out that target pyridazines <b>11e</b> and <b>11h</b> have no BBB permeability and thus could be used as antitumor agents with no predicted CNS concerns, whereas, compounds <b>11l</b> and <b>11m</b> have the ability to penetrate through the BBB and so they could be of great value for brain malignancies (<a href="#F0011">Figure 11</a>).</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 11.</span></a></div>   <p>Boiled-Egg chart for pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b>, and <b>11m</b>.</p>   </div> <p>The bioavailability radar plot (<a href="#F0012">Figure 12</a>) explains the extent of GIT absorption for the four examined pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b> and <b>11m</b>. The radar chart comprises six critical parameters for oral bioavailability; LIPO (Lipophilicity), INSOLU (Solubility), INSATU (saturation), FLEX (Flexibility), SIZE (SIZE), and POLAR (polarity). The pink area of the radar chart represents the optimal range for each property value within the six properties, while the red lines represents the predicted physicochemical features for the examined pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b> and <b>11m</b>, <a href="#F0012">Figure 12</a>.</p> <div class="fig" title="fig"> <div class="figure" title="figure"><a href="http://doi.org/"><span class="label" tagx="label" title="label">Figure 12.</span></a></div>   <p>The oral bioavailability radar chart for pyridazines <b>11e (A)</b>, <b>11h (B)</b>, <b>11l (C)</b> and <b>11m (D)</b>, produced by swissADME online web tool.</p>   </div> <p>All the predicted physicochemical properties for pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b> and <b>11m</b> were located in the desired pink area for all the six parameters, with an exception for compound <b>11e</b> which barely violated the LIPO (Lipophilicity) and INSOLU (Solubility) parameters (<a href="#F0012">Figure 12</a>), which clarifies its location outside the region of HIA in the BOILED-Egg graph. The other three compounds (<b>11h</b>, <b>11l</b> and <b>11m</b>) have the optimal combination of physicochemical properties that guaranteed a high GIT absorption with no single violation to any component of the bioavailability radar chart.</p> <p>The metabolism for the four pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b> and <b>11m</b> are predicted to take place partially in the liver by one or more of the five major Cytochrome P (CYP) isoforms (CYP2C9, CYP1A2, CYP2D6, CYP2C19, CYP3A4), and thus target pyridazines are suggested to be administered alone to minimise the possible drug-drug interactions. In details, pyridazines <b>11e</b>, <b>11h</b> and <b>11l</b> are predicted to exert inhibition for two of CYP isoforms. Compound <b>11e</b> was predicted to inhibit CYP2D6 and CYP3A4, compound <b>11h</b> was predicted to inhibit CYP2C19 and CYP3A4, and compound <b>11l</b> was predicted to inhibit CYP1A2 and CYP2D6. Furthermore, compound <b>11m</b> was predicted to inhibit CYP1A2 only (<a href="#t0006">Table 6</a>).</p> <div class="table-wrap_UNKNOWN" id="t0006" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 6.</span> <p>The <i>in silico</i> predicted ADME for pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b>, and <b>11m</b>.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup>  <thead> <tr> <th align="left">Cpd.</th> <th align="center">BBB</th> <th align="center">GIA</th> <th align="center">P-gP substrate</th> <th align="center">CYP1A2 inhibitor</th> <th align="center">CYP2C19 inhibitor</th> <th align="center">CYP2C9 inhibitor</th> <th align="center">CYP2D6 inhibitor</th> <th align="center">CYP3A4 inhibitor</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>11e</b></td> <td align="left">No</td> <td align="left">Low</td> <td align="left">Yes</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> <td align="left">Yes</td> <td align="left">Yes</td> </tr> <tr> <td align="left"><b>11h</b></td> <td align="left">No</td> <td align="left">High</td> <td align="left">No</td> <td align="left">No</td> <td align="left">Yes</td> <td align="left">No</td> <td align="left">No</td> <td align="left">Yes</td> </tr> <tr> <td align="left"><b>11l</b></td> <td align="left">Yes</td> <td align="left">High</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">No</td> <td align="left">No</td> <td align="left">Yes</td> <td align="left">No</td> </tr> <tr> <td align="left"><b>11m</b></td> <td align="left">Yes</td> <td align="left">High</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>GIA: gastrointestinal absorption; BBB: Blood Brain Barrier; PgP: P-glyco protein transporter.</p> </div> </div> </div> <p>On another note, SwissADME online web tool revealed that all the examined pyridazines were found to comply with all druglikeness rules defined by the pioneer pharmaceutical companies; Veberâ€™s (GSK)<a href="#CIT0040"><sup>40</sup></a>, Lipinskiâ€™s (Pfizer)<a href="#CIT0041"><sup>41</sup></a>, Eganâ€™s (Pharmacia)<a href="#CIT0042"><sup>42</sup></a>, Ghoseâ€™s (Amgen)<a href="#CIT0043"><sup>43</sup></a> and Mueggeâ€™s (Bayer)<a href="#CIT0044"><sup>44</sup></a> filters, with an exception for compound <b>11e</b> (towards Egan, Ghose and Muegge rules) and compound <b>11h</b> (towards Egan and Ghose rules) (<a href="#t0007">Table 7</a>). Interestingly enough, from the medicinal chemistry point of view the four examined pyridazines have neither PAINS (Pan Assay Interference Structures)<a href="#CIT0045"><sup>45</sup></a> alerts nor Brenks (Structural) alerts<a href="#CIT0046"><sup>46</sup></a>, which emphasises that their chemical structures lack any interfering framework that could result in an artefact in any protein assay implying that the obtained results from the <i>inÂ vitro</i> biological assays are to be robust.</p> <div class="table-wrap_UNKNOWN" id="t0007" orientation="portrait" position="float"><span class="label" tagx="label" title="label">Table 7.</span> <p>Compliance with Druglikeness rules (Lipinski, Veber, Egan, Ghose and Muegge), as well as PAINS and Brenk filters for target pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b>, and <b>11m</b>.</p>  <table frame="hsides" rules="groups"> <colgroup> <col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup> <colgroup><col width="1*" /></colgroup>  <thead> <tr> <th align="left">Cpd.</th> <th align="center">Lipinski violations</th> <th align="center">Veber violations</th> <th align="center">Muegge violations</th> <th align="center">Egan violations</th> <th align="center">Ghose violations</th> <th align="center">PAINS alerts</th> <th align="center">Brenk alerts</th> </tr> </thead> <tbody valign="top"> <tr> <td align="left"><b>11e</b></td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">No</td> <td align="left">No</td> <td align="left">No</td> <td align="left">0</td> <td align="left">0</td> </tr> <tr> <td align="left"><b>11h</b></td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">No</td> <td align="left">No</td> <td align="left">0</td> <td align="left">0</td> </tr> <tr> <td align="left"><b>11l</b></td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">0</td> <td align="left">0</td> </tr> <tr> <td align="left"><b>11m</b></td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">Yes</td> <td align="left">0</td> <td align="left">0</td> </tr> </tbody> </table> <div class="table-wrap-foot_UNKNOWN"> <div class="fn-type-" title=""> <p>PAINS: Pan Assay Interference Structures.</p> </div> </div> </div> <p>In conclusion, the four lead pyridazines (<b>11e</b>, <b>11h</b>, <b>11l</b> and <b>11m</b>) proved not only efficient biological actions but also an acceptable ADME and physicochemical properties, in particular pyridazines <b>11l</b> and <b>11m</b>.</p> </div> </div> <div class="materialsandmethods" title="sec"><span class="label" tagx="label" title="label">3.</span><div class="title" tagx="title" title="title">
Materials and methods</div> <div class="chemistry" title="sec"><span class="label" tagx="label" title="label">3.1.</span><div class="title" tagx="title" title="title">
Chemistry</div> <div class="general" title="sec"><span class="label" tagx="label" title="label">3.1.1.</span><div class="title" tagx="title" title="title">
General</div> <p>Melting points have been obtained on a BÃ¼chi Melting PointB-540 apparatus which uncorrected and determined. <sup>1</sup>H NMR spectra have been recorded on a Bruker Advance III instrument at 400â€‰MHz. Chemical shifts (<i>Î´</i>) of NMR have been reported in parts per million (<i>ppm</i>) units relative to internal standard (TMS). All reactions have been monitored by thin-layer chromatography (TLC), using silica gel plates (GF254) and UV light visualisation. Flash chromatography separations have been obtained on silica gel (200â€"300 mesh).</p> </div> <div class="synthesisofethyl2-hydroxy-4-oxo-2-(trifluoromethyl)pentanoate(2)" title="sec"><span class="label" tagx="label" title="label">3.1.2.</span><div class="title" tagx="title" title="title">
Synthesis of ethyl 2-hydroxy-4-oxo-2-(trifluoromethyl)pentanoate (2)</div> <p>Compound 2 was reported previously<a href="#CIT0031"><sup>31</sup></a>.</p> </div> <div class="synthesisof6-methyl-4-(trifluoromethyl)pyridazin-3(2h)-one(3)" title="sec"><span class="label" tagx="label" title="label">3.1.3.</span><div class="title" tagx="title" title="title">
Synthesis of 6-methyl-4-(trifluoromethyl)pyridazin-3(2H)-one (3)</div> <p>A solution of ethyl 2-hydroxy-4-oxo-2-(trifluoromethyl)pentanoate <b>2</b> (0.45â€‰g, 2â€‰mmol) and 99% hydrazine monohydrate (0.53â€‰ml, 11â€‰mmol) in acetic acid (7â€‰ml), was refluxed with stirring for 6â€‰h. The solution was then poured into H<sub>2</sub>O and extracted with EtOAc, dried by NaSO<sub>4</sub> and purified by column flash chromatography (petroleum ether/EtOAc 70:30) to produce pyridazinone <b>3</b> as white crystals (0.27â€‰g, 69%); m.p. 184â€"185â€‰Â°C (reported m.p. 187â€"189â€‰Â°C<a href="#CIT0032"><sup>32</sup></a>).</p> </div> <div class="synthesisof6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazine-3-carboxylicacid(4)" title="sec"><span class="label" tagx="label" title="label">3.1.4.</span><div class="title" tagx="title" title="title">
Synthesis of 6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazine-3-carboxylic acid (4)</div> <p>Pyridazinone <b>3</b> (0.1â€‰g, 0.561â€‰mmol) was dissolved in conc. H<sub>2</sub>SO<sub>4</sub> (5â€‰ml) and stirred at 0â€‰Â°C, then K<sub>2</sub>Cr<sub>2</sub>O<sub>7</sub> (0.24â€‰g, 0.846â€‰mmol) was added portionwise. The reaction mixture was left to be stir at r.t. overnight, then added to ice-water and extracted to be extracted with ethyl acetate. The organic phases were dried with NaSO<sub>4</sub> and concentrated under reduced pressure and the residue was purified by flash chromatography (DCM/MeOH: 90/10) to obtain pyridazine-3-carboxylic acid derivative <b>4</b> as white crystals (0.06â€‰g, 54%); m.p. 239â€"240â€‰Â°C.</p> </div> <div class="synthesisofethyl6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazine-3-carboxylate(5)" title="sec"><span class="label" tagx="label" title="label">3.1.5.</span><div class="title" tagx="title" title="title">
Synthesis of ethyl 6-oxo-5-(trifluoromethyl)-1,6-dihydropyridazine-3-carboxylate (5)</div> <p>Dihydropyridazine-3-carboxylic acid derivative <b>4</b> (2.4â€‰g, 11.5â€‰mmol) was dissolved in ethanol (18â€‰ml) and H<sub>2</sub>SO<sub>4</sub> (0.5â€‰ml), then the reaction mixture was heated under reflux for 4â€‰h. The solution was extracted with ethyl acetate and purified by column chromatography (petroleum ether / EtOAc 70:30) to produce white solid (3.0â€‰g, 90%); m.p. 147â€"148â€‰Â°C.</p> </div> <div class="synthesisofethyl6-chloro-5-(trifluoromethyl)pyridazine-3-carboxylate(6)" title="sec"><span class="label" tagx="label" title="label">3.1.6.</span><div class="title" tagx="title" title="title">
Synthesis of ethyl 6-chloro-5-(trifluoromethyl) pyridazine-3-carboxylate (6)</div> <p>Ethyl 6-oxo dihydropyridazine-3-carboxylate derivative <b>5</b> (2â€‰g, 8.47â€‰mmol) was added portionwise to a cooled stirred phosphorus oxychloride (POCl<sub>3</sub>) (10â€‰ml) which subsequently heated at 100â€‰Â°C for 5â€‰h. The reaction mixture, after cooling, was poured into iced-water, neutralised by aqueous solution of sodium hydroxide, extracted with ethyl acetate and purified by column chromatography (petroleum ether/EtOAc 85:15) to yield ester <b>6</b> as yellow oil (1.1â€‰g, 51%).</p> </div> <div class="generalproceduresforpreparationof6-chloro-5-(trifluoromethyl)pyridazine-3-carboxamidederivatives(9aâ€" title="sec"><span class="label" tagx="label" title="label">3.1.7.</span><div class="title" tagx="title" title="title">
General procedures for preparation of 6-chloro-5-(trifluoromethyl)pyridazine-3-carboxamide derivatives (9aâ€"e)</div> <p>Ethyl 6-chloro-5-(trifluoromethyl)pyridazine-3-carboxylate <b>6</b> (0.04â€‰g, 0.16â€‰mmol) was added to a mixture of THF/H<sub>2</sub>O (4:1) and LiOH hydrate (0.80â€‰mmol) at 0â€‰Â°C, then the reaction mixture was stirred for 1â€‰h at room temperature. The reaction mixture was then evaporated to dryness and the residue was dissolved in H<sub>2</sub>O, neutralised carefully with a 1â€‰N HCl, and extracted with ethyl acetate. Organic layers were collected, dried over anhydrous sodium sulphate, filtered and the solvent was removed under reduced pressure to yield the corresponding carboxylic acid. The later acid derivative was dissolved in dry 1,2-dichloroethane (5â€‰ml), then thionyl chloride (0.9â€‰mmol) and DMF (2â€"3 drops) were added to the solution. The mixture was refluxed for 3â€‰h then evaporated to dryness to produce the crude product of acyl chloride <b>7</b>. This compound was used immediately for the next step to prepare key amide intermediates <b>9aâ€"e</b><i>via</i> stirring with primary amines <b>8aâ€"e</b> (0.32â€‰mmol) in methylene chloride (4â€‰ml) and in the presence of TEA (0.80â€‰mmol) for 4â€‰h at room temperature. The obtained precipitate was filtered off and washed with petroleum ether, then used in the next step without further purification.</p> </div> <div class="synthesisofethyl6-morpholino-5-(trifluoromethyl)pyridazine-3-carboxylate(13)" title="sec"><span class="label" tagx="label" title="label">3.1.8.</span><div class="title" tagx="title" title="title">
Synthesis of ethyl 6-morpholino-5-(trifluoromethyl)pyridazine-3-carboxylate (13)</div> <p>A mixture of ethyl 6-chloro-5-(trifluoromethyl)pyridazine-3-carboxylate <b>6</b> (0.06â€‰g, 0.23â€‰mmol), morpholine <b>12</b> (0.1â€‰g, 1.12â€‰mmol) and HÃ¼nigâ€™s base (0.29â€‰g, 2.24â€‰mmol) were dissolved in 1,4-dioxane (10â€‰ml), and the reaction mixture was heated under reflux for 12â€‰h. After cooling to room temperature, the reaction mixture was evaporated under reduced pressure and the residue was dissolved in ethyl acetate and washed with H<sub>2</sub>O. The organic layer was then dried, evaporated <i>in vacuo</i> and purified with flash chromatography on silica gel (petroleum ether/EtOAc 70/30) to obtain compound <b>13</b> as yellow oil (0.0476â€‰g, 70%).</p> </div> <div class="generalproceduresforthepreparationoftargetpyridazinederivatives(11a-r)" title="sec"><span class="label" tagx="label" title="label">3.1.9.</span><div class="title" tagx="title" title="title">
General procedures for the preparation of target pyridazine derivatives (11a-r)</div> <div class="route(a)" title="sec"><span class="label" tagx="label" title="label">3.1.9.1.</span><div class="title" tagx="title" title="title">
Route (A)</div> <p>The appropriate aliphatic amine <b>8a</b>, <b>8e</b> and <b>10a</b>â€"<b>d</b> (5â€‰mmol) and HÃ¼nigâ€™s base (1.3â€‰g, 10â€‰mmol) were added to a solution of intermediates <b>9aâ€"e</b> (1â€‰mmol) in dioxane (5â€‰ml), and then the reaction mixture was refluxed for 6â€‰h. After the reaction completed, the excess dioxane was evaporated under reduced pressure, the residue was dissolved in ethyl acetate and washed with water and the organic layer was dried over anhydrous Na<sub>2</sub>SO4, and evaporated <i>in vacuo</i>. The crude product was purified by flash chromatography (petroleum ether: ethyl acetate 70:30) to yield target pyridazine <b>11aâ€"r</b>.</p> </div> <div class="route(b)" title="sec"><span class="label" tagx="label" title="label">3.1.9.2.</span><div class="title" tagx="title" title="title">
Route (B)</div> <p>Ethyl 6-morpholino-5-(trifluoromethyl)pyridazine-3-carboxylate <b>(13)</b> (2.54â€‰g, 10â€‰mmol) was dissolved in ethyl alcohol (8â€‰ml), then primary amines (<b>8a</b>â€"<b>e</b>) (15â€‰mmol) and piperidine (2â€"3 drops) were added. The reaction mixture was refluxed for 6â€‰h and then the solvent was evaporated under reduce pressure. The crude product was purified by using flash column chromatography (petroleum ether: ethyl acetate 70:30) to afford the corresponding target pyridazines <b>11d</b>, <b>11g</b>, <b>11i</b>, <b>11m</b> and <b>11r</b>, respectively<a href="#CIT0033"><sup>33</sup></a>.</p> <p>For the full characterisation details for the intermediates and the target pyridazines 11a-r have been provided in the <a href="https://doi.org/10.1080/14756366.2020.1806259">Supplementary Materials</a>.</p> </div> </div> </div> <div class="biologicalevaluations" title="sec"><span class="label" tagx="label" title="label">3.2.</span><div class="title" tagx="title" title="title">
Biological evaluations</div> <p>The utilised procedures in the biological assays were performed as described earlier; cytotoxicity<a href="#CIT0047"><sup>47</sup></a>, cell cycle<a href="#CIT0048"><sup>48</sup></a>, Annexin V-FITC Apoptosis<a href="#CIT0049"><sup>49</sup></a> and CDK2<a href="#CIT0050"><sup>50</sup></a> assays, whereas all detailed procedures were mentioned in the <a href="https://doi.org/10.1080/14756366.2020.1806259">Supplementary Materials</a>.</p> </div> <div class="insilicostudies" title="sec"><span class="label" tagx="label" title="label">3.3.</span><div class="title" tagx="title" title="title">
In silico studies</div> <div class="insilicotargetprediction" title="sec"><span class="label" tagx="label" title="label">3.3.1.</span><div class="title" tagx="title" title="title">
In silico target prediction</div> <p>To deduce a potential mechanism of action for herein reported target pyridazines <b>11</b>, the SwissTargetPrediction online tool was utilised<a href="#CIT0035"><sup>35</sup></a>. Two representative compounds <b>11a</b> and <b>11j</b> were drawn and submitted to the server for target prediction.</p> </div> <div class="dockingstudies" title="sec"><span class="label" tagx="label" title="label">3.3.2.</span><div class="title" tagx="title" title="title">
Docking studies</div> <p>The crystal structure of CDK2 in complex with roniciclib was collected from the protein data bank PDB ID (5iev) <a href="#CIT0051"><sup>51</sup></a>. The molecular docking procedures reliability was ensured through re-docking of the co-crystalized roniciclib in the vicinity of the CDK2 binding site, as mentioned above in the discussion section. Molecular docking of the target pyridazines into CDK2 active site was conducted by Vina Autodock, a more accurate and twice speed higher than Autodock 4 software<a href="#CIT0052"><sup>52</sup></a>. Vina Autodock requires both ligands and receptors in pdbqt format, thus, MGL tools 1.5.7 were used to prepare all the necessary files to carry out the docking<a href="#CIT0053"><sup>53</sup></a>. Also the MGL tools were used to generate a grid box around the binding site of Roniciclib. The docking results were visualised by Biovia discovery studio 2020 free visualiser<a href="#CIT0054"><sup>54</sup></a>, and then the best scoring candidates were selected for further investigation.</p> </div> <div class="insilicoadmecalculationanddrug-likenesspropertiesprediction" title="sec"><span class="label" tagx="label" title="label">3.3.3.</span><div class="title" tagx="title" title="title">
In silico ADME calculation and Drug-Likeness properties prediction</div> <p>The SwissADME online tool was utilised to calculate the ADME profiles for target pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b> and <b>11m</b>, in addition to prediction of their medicinal chemistry friendliness and drug-likeness properties<a href="#CIT0038"><sup>38</sup></a>.</p> </div> </div> </div> <div class="conclusions" title="sec"><span class="label" tagx="label" title="label">4.</span><div class="title" tagx="title" title="title">
Conclusions</div> <p>To the best of our knowledge, this is the first study that reports on 3,6-disubstituted pyridazines as anticancer CDK inhibitors. Herein, a new series of 3,6-disubstituted pyridazines <b>11aâ€"r</b> has been synthesised, characterised and evaluated for <i>inÂ vitro</i> anticancer activity against three human cancer cell lines, namely, T-47D (breast cancer), MDA-MB-231 (breast cancer) and SKOV-3 (ovarian cancer) cell lines by the SRB assay. While, the examined pyridazines elicited good activity against T-47D cells (IC<sub>50</sub> range: 0.43â€‰Â±â€‰0.01â€‰âˆ’â€‰35.9â€‰Â±â€‰1.18â€‰ÂµM) and MDA-MB-231 cells (IC<sub>50</sub> range: 0.99â€‰Â±â€‰0.03â€‰âˆ’â€‰34.59â€‰Â±â€‰1.13â€‰ÂµM), they exerted weak activity against SKOV-3 cells. Uniquely, the methyltetrahydropyran-bearing pyridazine <b>11m</b> showed a submicromolar growth inhibitory potency towards both breast T-47D and MDA-MB-231 (IC<sub>50</sub> = 0.43â€‰Â±â€‰0.01 and 0.99â€‰Â±â€‰0.03â€‰ÂµM, respectively) cell lines. In addition, the biological results indicated that pyridazines <b>11l</b> and <b>11m</b> exerted an efficient alteration in cell cycle progression and induction of apoptosis in both T-47D and MDA-MB-231 cells, alongside, with their good mean tumour selectivity indexes (13.7 and 16.1, respectively) upon assessment of their cytotoxicity towards non-tumorigenic breast MCF-10A cells. Based on a suggestion from a conducted <i>in silico</i> study, pyridazines <b>11e</b>, <b>11h</b>, <b>11l</b>, and <b>11m</b> were selected to be evaluated for their ability to inhibit CDK2, where they exerted good inhibitory activity (IC<sub>50</sub> = 151, 43.8, 55.6 and 20.1â€‰nM, respectively). Finally, the <i>in silico</i> study implied that target pyridazines <b>11</b> exhibited not only an efficient anticancer activity but also an acceptable ADME, physicochemical and druglikeness properties, specifically pyridazines <b>11l</b> and <b>11m</b>. Overall the obtained results from this study quite sustained our strategy and gave us a robust opportunity for further development and optimisation of 3,6-disubstituted pyridazine scaffold to enrich therapeutic arsenal with efficient and safe anticancer CDK inhibitors.</p> </div> <div class="supplementary-material" title="supplementary-material"> <div class="title" tagx="title" title="title">
Supplementary Material</div> <div class="local-data" title="local-data">  <div class="title" tagx="title" title="title">
Supplemental Material</div>  <div class="media" title="media"><a href="IENZ_A_1806259_SM2316.pdf">LINK</a> <p>Click here for additional data file.</p>  </div> </div> </div> </div> <div class="back" title="back"> <div class="COI-statement" title="COI-statement"> <div class="title" tagx="title" title="title">
Disclosure statement</div> <p>No potential conflict of interest was reported by the author(s).</p> </div> <div class="references">
References</div> <div tag="ref-list"> <ul> <div class="title" tagx="title" title="title">
References</div> <li tag="ref"><a name="CIT0001" /><span class="label" tagx="label" title="label">1</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Padma</span><span class="given-names" tagx="given-names" title="given-names">VV.</span></span></span><span class="mixed-article-title" title="mixed-article-title">An overview of targeted cancer therapy</span>. <span class="source" tagx="source" title="source">Biomedicine</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">5</span>:<span class="fpage" tagx="fpage" title="fpage">19</span>â€"<span class="lpage" tagx="lpage" title="lpage">6</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26613930">26613930</a></span></span></li> <li tag="ref"><a name="CIT0002" /><span class="label" tagx="label" title="label">2</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Siegel</span><span class="given-names" tagx="given-names" title="given-names">RL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Miller</span><span class="given-names" tagx="given-names" title="given-names">KD</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jemal</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cancer statistics 2016</span>. <span class="source" tagx="source" title="source">CA: Cancer J Clin</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">66</span>:<span class="fpage" tagx="fpage" title="fpage">7</span>â€"<span class="lpage" tagx="lpage" title="lpage">30</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26742998">26742998</a></span></span></li> <li tag="ref"><a name="CIT0003" /><span class="label" tagx="label" title="label">3</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lim</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kaldis</span><span class="given-names" tagx="given-names" title="given-names">P.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cdks, cyclins and CKIs: roles beyond cell cycle regulation</span>. <span class="source" tagx="source" title="source">Development</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">140</span>:<span class="fpage" tagx="fpage" title="fpage">3079</span>â€"<span class="lpage" tagx="lpage" title="lpage">93</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23861057">23861057</a></span></span></li> <li tag="ref"><a name="CIT0004" /><span class="label" tagx="label" title="label">4</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ingham</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Schwartz</span><span class="given-names" tagx="given-names" title="given-names">GK.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cell-cycle therapeutics come of age</span>. <span class="source" tagx="source" title="source">J. Clin. Oncol</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">35</span>:<span class="fpage" tagx="fpage" title="fpage">2949</span>â€"<span class="lpage" tagx="lpage" title="lpage">59</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28580868">28580868</a></span></span></li> <li tag="ref"><a name="CIT0005" /><span class="label" tagx="label" title="label">5</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cheng</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yang</span><span class="given-names" tagx="given-names" title="given-names">Z</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wang</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Q. Recent development of CDK inhibitors: an overview of CDK/inhibitor co-crystal structures</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">164</span>:<span class="fpage" tagx="fpage" title="fpage">615</span>â€"<span class="lpage" tagx="lpage" title="lpage">39</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30639897">30639897</a></span></span></li> <li tag="ref"><a name="CIT0006" /><span class="label" tagx="label" title="label">6</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Asghar</span><span class="given-names" tagx="given-names" title="given-names">U</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Witkiewicz</span><span class="given-names" tagx="given-names" title="given-names">AK</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Turner</span><span class="given-names" tagx="given-names" title="given-names">NC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Knudsen</span><span class="given-names" tagx="given-names" title="given-names">ES.</span></span></span><span class="mixed-article-title" title="mixed-article-title">The history and future of targeting cyclin-dependent kinases in cancer therapy</span>. <span class="source" tagx="source" title="source">Nat Rev Drug Discov</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">14</span>:<span class="fpage" tagx="fpage" title="fpage">130</span>â€"<span class="lpage" tagx="lpage" title="lpage">46</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25633797">25633797</a></span></span></li> <li tag="ref"><a name="CIT0007" /><span class="label" tagx="label" title="label">7</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Spring</span><span class="given-names" tagx="given-names" title="given-names">LM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wander</span><span class="given-names" tagx="given-names" title="given-names">SA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zangardi</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bardia</span><span class="given-names" tagx="given-names" title="given-names">A.</span></span></span><span class="mixed-article-title" title="mixed-article-title">CDK 4/6 inhibitors in breast cancer: current controversies and future directions</span>. <span class="source" tagx="source" title="source">Curr Oncol Rep</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">25</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30806829">30806829</a></span></span></li> <li tag="ref"><a name="CIT0008" /><span class="label" tagx="label" title="label">8</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Reck</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Horn</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Novello</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in patients with extensive-disease small cell lung cancer</span>. <span class="source" tagx="source" title="source">J Thorac Oncol</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">14</span>:<span class="fpage" tagx="fpage" title="fpage">701</span>â€"<span class="lpage" tagx="lpage" title="lpage">11</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30677506">30677506</a></span></span></li> <li tag="ref"><a name="CIT0009" /><span class="label" tagx="label" title="label">9</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Niu</span><span class="given-names" tagx="given-names" title="given-names">Y</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Xu</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sun</span><span class="given-names" tagx="given-names" title="given-names">T.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Cyclin-dependent kinases 4/6 inhibitors in breast cancer: current status, resistance, and combination strategies</span>. <span class="source" tagx="source" title="source">J Cancer</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">10</span>:<span class="fpage" tagx="fpage" title="fpage">5504</span>â€"<span class="lpage" tagx="lpage" title="lpage">17</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31632494">31632494</a></span></span></li> <li tag="ref"><a name="CIT0010" /><span class="label" tagx="label" title="label">10</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ritchie</span><span class="given-names" tagx="given-names" title="given-names">TJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Macdonald</span><span class="given-names" tagx="given-names" title="given-names">SJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Peace</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The developability of heteroaromatic and heteroaliphatic ringsâ€"do some have a better pedigree as potential drug</span>. <span class="source" tagx="source" title="source">Med Chem Comm</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">3</span>:<span class="fpage" tagx="fpage" title="fpage">1062</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.</span></li> <li tag="ref"><a name="CIT0011" /><span class="label" tagx="label" title="label">11</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahmed</span><span class="given-names" tagx="given-names" title="given-names">EM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hassan</span><span class="given-names" tagx="given-names" title="given-names">MS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El-Malah</span><span class="given-names" tagx="given-names" title="given-names">AA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kassab</span><span class="given-names" tagx="given-names" title="given-names">AE.</span></span></span><span class="mixed-article-title" title="mixed-article-title">New pyridazine derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents; design, synthesis and biological evaluation</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">95</span>:<span class="fpage" tagx="fpage" title="fpage">103497</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31838289">31838289</a></span></span></li> <li tag="ref"><a name="CIT0012" /><span class="label" tagx="label" title="label">12</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Barberot</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Moniot</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Allart-Simon</span><span class="given-names" tagx="given-names" title="given-names">I</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">146</span>:<span class="fpage" tagx="fpage" title="fpage">139</span>â€"<span class="lpage" tagx="lpage" title="lpage">46</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29407945">29407945</a></span></span></li> <li tag="ref"><a name="CIT0013" /><span class="label" tagx="label" title="label">13</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Costas</span><span class="given-names" tagx="given-names" title="given-names">T</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Besada</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Piras</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">New pyridazinone derivatives with vasorelaxant and platelet antiaggregatory activities</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">20</span>:<span class="fpage" tagx="fpage" title="fpage">6624</span>â€"<span class="lpage" tagx="lpage" title="lpage">7</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20880705">20880705</a></span></span></li> <li tag="ref"><a name="CIT0014" /><span class="label" tagx="label" title="label">14</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rathish</span><span class="given-names" tagx="given-names" title="given-names">IG</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Javed</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bano</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and blood glucose lowering effect of novel pyridazinone substituted benzenesulfonylurea derivatives</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">44</span>:<span class="fpage" tagx="fpage" title="fpage">2673</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19171410">19171410</a></span></span></li> <li tag="ref"><a name="CIT0015" /><span class="label" tagx="label" title="label">15</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Roth</span><span class="given-names" tagx="given-names" title="given-names">GJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Heckel</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kley</span><span class="given-names" tagx="given-names" title="given-names">JT</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis and evaluation of MCH receptor 1 antagonists-Part II: optimization of pyridazines toward reduced phospholipidosis and hERG inhibition</span>. <span class="source" tagx="source" title="source">Bioorg. Med. Chem. Lett</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">25</span>:<span class="fpage" tagx="fpage" title="fpage">3270</span>â€"<span class="lpage" tagx="lpage" title="lpage">4</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26077492">26077492</a></span></span></li> <li tag="ref"><a name="CIT0016" /><span class="label" tagx="label" title="label">16</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Costas-Lago</span><span class="given-names" tagx="given-names" title="given-names">MC</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Besada</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">RodrÃ­guez-EnrÃ­quez</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and structure-activity relationship study of novel 3-heteroarylcoumarins based on pyridazine scaffold as selective MAO-B inhibitors</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">139</span>:<span class="fpage" tagx="fpage" title="fpage">1</span>â€"<span class="lpage" tagx="lpage" title="lpage">11</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28797881">28797881</a></span></span></li> <li tag="ref"><a name="CIT0017" /><span class="label" tagx="label" title="label">17</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kilic</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gulcan</span><span class="given-names" tagx="given-names" title="given-names">HO</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Aksakal</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design and synthesis of some new carboxamide and propanamide derivatives bearing phenylpyridazine as a core ring and the investigation of their inhibitory potential on in-vitro acetylcholinesterase and butyrylcholinesterase</span>. <span class="source" tagx="source" title="source">Bioorg Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">79</span>:<span class="fpage" tagx="fpage" title="fpage">235</span>â€"<span class="lpage" tagx="lpage" title="lpage">49</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/29775949">29775949</a></span></span></li> <li tag="ref"><a name="CIT0018" /><span class="label" tagx="label" title="label">18</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Tan</span><span class="given-names" tagx="given-names" title="given-names">OU</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ozadali</span><span class="given-names" tagx="given-names" title="given-names">K</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Yogeeswari</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and antimycobacterial activities of some new N-acylhydrazone and thiosemicarbazide derivatives of 6-methyl-4,5-dihydropyridazin-3(2H)-one</span>. <span class="source" tagx="source" title="source">Med Chem Res</span><span class="year" tagx="year" title="year">2012</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">2388</span>â€"<span class="lpage" tagx="lpage" title="lpage">94</span>.</span></li> <li tag="ref"><a name="CIT0019" /><span class="label" tagx="label" title="label">19</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Li</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zhan</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Liu</span><span class="given-names" tagx="given-names" title="given-names">H</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of pyridazine derivatives as novel HIV-1 NNRTIs</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">2128</span>â€"<span class="lpage" tagx="lpage" title="lpage">34</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23415090">23415090</a></span></span></li> <li tag="ref"><a name="CIT0020" /><span class="label" tagx="label" title="label">20</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jaballah</span><span class="given-names" tagx="given-names" title="given-names">MY</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Serya</span><span class="given-names" tagx="given-names" title="given-names">RT</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abouzid</span><span class="given-names" tagx="given-names" title="given-names">K.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Pyridazine based scaffolds as privileged structures in anti-cancer therapy</span>. <span class="source" tagx="source" title="source">Drug Res (Stuttg)</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">67</span>:<span class="fpage" tagx="fpage" title="fpage">138</span>â€"<span class="lpage" tagx="lpage" title="lpage">48</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28073115">28073115</a></span></span></li> <li tag="ref"><a name="CIT0021" /><span class="label" tagx="label" title="label">21</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Bongartz</span><span class="given-names" tagx="given-names" title="given-names">JP</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Stokbroekx</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Van der Aa</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and anti-angiogenic activity of 6-(1,2,4-thiadiazol-5-yl)-3-amino pyridazine derivatives</span>. <span class="source" tagx="source" title="source">Bioorg Med ChemLett</span><span class="year" tagx="year" title="year">2002</span>;<span class="volume" tagx="volume" title="volume">12</span>:<span class="fpage" tagx="fpage" title="fpage">589</span>â€"<span class="lpage" tagx="lpage" title="lpage">91</span>.</span></li> <li tag="ref"><a name="CIT0022" /><span class="label" tagx="label" title="label">22</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abouzid</span><span class="given-names" tagx="given-names" title="given-names">KA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Khalil</span><span class="given-names" tagx="given-names" title="given-names">NA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahmed</span><span class="given-names" tagx="given-names" title="given-names">EM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Mohamed</span><span class="given-names" tagx="given-names" title="given-names">KO.</span></span></span><span class="mixed-article-title" title="mixed-article-title">[(3-[(6-Arylamino)pyridazinylamino]benzoic acids: design, synthesis and inÂ vitro evaluation of anticancer activity</span>. <span class="source" tagx="source" title="source">Arch Pharm Res</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">36</span>:<span class="fpage" tagx="fpage" title="fpage">41</span>â€"<span class="lpage" tagx="lpage" title="lpage">50</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/23307426">23307426</a></span></span></li> <li tag="ref"><a name="CIT0023" /><span class="label" tagx="label" title="label">23</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Park</span><span class="given-names" tagx="given-names" title="given-names">EH</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Park</span><span class="given-names" tagx="given-names" title="given-names">MS.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Novel alkylaminopyridazine derivatives: synthesis and their anti-proliferative effects against MCF-7 cells</span>. <span class="source" tagx="source" title="source">Bull Korean Chem Soc</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">34</span>:<span class="fpage" tagx="fpage" title="fpage">3317</span>â€"<span class="lpage" tagx="lpage" title="lpage">21</span>.</span></li> <li tag="ref"><a name="CIT0024" /><span class="label" tagx="label" title="label">24</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">SB</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Park</span><span class="given-names" tagx="given-names" title="given-names">MS.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis of novel 3-allylseleno-6-alkylthiopyridazines: their anticancer activity against MCF-7 cells</span>. <span class="source" tagx="source" title="source">Arch Pharm Res</span><span class="year" tagx="year" title="year">2014</span>;<span class="volume" tagx="volume" title="volume">37</span>:<span class="fpage" tagx="fpage" title="fpage">452</span>â€"<span class="lpage" tagx="lpage" title="lpage">8</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24068458">24068458</a></span></span></li> <li tag="ref"><a name="CIT0025" /><span class="label" tagx="label" title="label">25</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Park</span><span class="given-names" tagx="given-names" title="given-names">HS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kim</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Park</span><span class="given-names" tagx="given-names" title="given-names">MS.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Discovery and synthesis of novel allylthioaralkylthiopyridazines: their antiproliferative activity against MCF-7 and Hep3B cells</span>. <span class="source" tagx="source" title="source">Arch Pharm Res</span><span class="year" tagx="year" title="year">2015</span>;<span class="volume" tagx="volume" title="volume">38</span>:<span class="fpage" tagx="fpage" title="fpage">791</span>â€"<span class="lpage" tagx="lpage" title="lpage">800</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24925344">24925344</a></span></span></li> <li tag="ref"><a name="CIT0026" /><span class="label" tagx="label" title="label">26</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">George</span><span class="given-names" tagx="given-names" title="given-names">RF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Fouad</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gomaa</span><span class="given-names" tagx="given-names" title="given-names">IEO.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and cytotoxic activities of some pyrazoline derivatives bearing phenyl pyridazine core as new apoptosis inducers</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">112</span>:<span class="fpage" tagx="fpage" title="fpage">48</span>â€"<span class="lpage" tagx="lpage" title="lpage">59</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/26874744">26874744</a></span></span></li> <li tag="ref"><a name="CIT0027" /><span class="label" tagx="label" title="label">27</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Elmeligie</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ahmed</span><span class="given-names" tagx="given-names" title="given-names">EM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abuel-Maaty</span><span class="given-names" tagx="given-names" title="given-names">SM</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Design and synthesis of pyridazine containing compounds with promising anticancer activity</span>. <span class="source" tagx="source" title="source">Chem Pharm Bull</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">65</span>:<span class="fpage" tagx="fpage" title="fpage">236</span>â€"<span class="lpage" tagx="lpage" title="lpage">47</span>.</span></li> <li tag="ref"><a name="CIT0028" /><span class="label" tagx="label" title="label">28</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sengmany</span><span class="given-names" tagx="given-names" title="given-names">S</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sitter</span><span class="given-names" tagx="given-names" title="given-names">M</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">LÃ©one</span><span class="given-names" tagx="given-names" title="given-names">E</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and biological evaluation of 3-amino-, 3-alkoxy- and 3-aryloxy-6-(hetero)arylpyridazines as potent antitumor agents</span>. <span class="source" tagx="source" title="source">Bioorg Med Chem Lett</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">29</span>:<span class="fpage" tagx="fpage" title="fpage">755</span>â€"<span class="lpage" tagx="lpage" title="lpage">60</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/30655216">30655216</a></span></span></li> <li tag="ref"><a name="CIT0029" /><span class="label" tagx="label" title="label">29</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Jaballah</span><span class="given-names" tagx="given-names" title="given-names">MY</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Serya</span><span class="given-names" tagx="given-names" title="given-names">RAT</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Saad</span><span class="given-names" tagx="given-names" title="given-names">N</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Towards discovery of novel scaffold with potent antiangiogenic activity; design, synthesis of pyridazine based compounds, impact of hinge interaction, and accessibility of their bioactive conformation on VEGFR-2 activities</span>. <span class="source" tagx="source" title="source">J Enzyme Inhib Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">34</span>:<span class="fpage" tagx="fpage" title="fpage">1573</span>â€"<span class="lpage" tagx="lpage" title="lpage">89</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31852269">31852269</a></span></span></li> <li tag="ref"><a name="CIT0030" /><span class="label" tagx="label" title="label">30</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ali</span><span class="given-names" tagx="given-names" title="given-names">YM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ismail</span><span class="given-names" tagx="given-names" title="given-names">MF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abu Elâ€�Azm</span><span class="given-names" tagx="given-names" title="given-names">FS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Marzouk</span><span class="given-names" tagx="given-names" title="given-names">MI.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Design, synthesis, and pharmacological assay of novel compounds based on pyridazine moiety as potential antitumor agents</span>. <span class="source" tagx="source" title="source">J Heterocycl Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">56</span>:<span class="fpage" tagx="fpage" title="fpage">2580</span>â€"<span class="lpage" tagx="lpage" title="lpage">91</span>.</span></li> <li tag="ref"><a name="CIT0031" /><span class="label" tagx="label" title="label">31</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Landge</span><span class="given-names" tagx="given-names" title="given-names">SM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">TÃ¶rÃ¶k</span><span class="given-names" tagx="given-names" title="given-names">B.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Highly enantioselective organocatalytic addition of ethyl trifluoropyruvate to ketones with subzero temperature microwave activation</span>. <span class="source" tagx="source" title="source">Catal Lett</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">131</span>:<span class="fpage" tagx="fpage" title="fpage">432</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.</span></li> <li tag="ref"><a name="CIT0032" /><span class="label" tagx="label" title="label">32</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sibgatulin</span><span class="given-names" tagx="given-names" title="given-names">DA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Volochnyuk</span><span class="given-names" tagx="given-names" title="given-names">DM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kostyuk</span><span class="given-names" tagx="given-names" title="given-names">AN.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A convenient synthesis of 4-trifluoromethyl-(2H)-pyridazin-3-ones from methyl 3,3,3-trifluoropyruvate</span>. <span class="source" tagx="source" title="source">Synlett</span><span class="year" tagx="year" title="year">2005</span>;<span class="volume" tagx="volume" title="volume">2005</span>:<span class="fpage" tagx="fpage" title="fpage">1907</span>â€"<span class="lpage" tagx="lpage" title="lpage">11</span>.</span></li> <li tag="ref"><a name="CIT0033" /><span class="label" tagx="label" title="label">33</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Siddiqui</span><span class="given-names" tagx="given-names" title="given-names">FA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Alam</span><span class="given-names" tagx="given-names" title="given-names">C</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Rosenqvist</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">PDE6D inhibitors with a new design principle selectively block K-ras activity</span>. <span class="source" tagx="source" title="source">ACS Omega</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">5</span>:<span class="fpage" tagx="fpage" title="fpage">832</span>â€"<span class="lpage" tagx="lpage" title="lpage">42</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31956834">31956834</a></span></span></li> <li tag="ref"><a name="CIT0034" /><span class="label" tagx="label" title="label">34</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Skehan</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Storeng</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Scudiero</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">New colorimetric cyto-toxicity assay for anticancer-drug screening</span>. <span class="source" tagx="source" title="source">J Natl Cancer Inst</span><span class="year" tagx="year" title="year">1990</span>;<span class="volume" tagx="volume" title="volume">82</span>:<span class="fpage" tagx="fpage" title="fpage">1107</span>â€"<span class="lpage" tagx="lpage" title="lpage">12</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/2359136">2359136</a></span></span></li> <li tag="ref"><a name="CIT0035" /><span class="label" tagx="label" title="label">35</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Daina</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Michielin</span><span class="given-names" tagx="given-names" title="given-names">O</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zoete</span><span class="given-names" tagx="given-names" title="given-names">V.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Swiss TargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules</span>. <span class="source" tagx="source" title="source">Nucl Acids Res</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">47</span>:<span class="fpage" tagx="fpage" title="fpage">357</span>â€"<span class="lpage" tagx="lpage" title="lpage">64</span>.</span></li> <li tag="ref"><a name="CIT0036" /><span class="label" tagx="label" title="label">36</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Gfeller</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Michielin</span><span class="given-names" tagx="given-names" title="given-names">O</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zoete</span><span class="given-names" tagx="given-names" title="given-names">V.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Shaping the interaction landscape of bioactive molecules</span>. <span class="source" tagx="source" title="source">Bioinformatics</span><span class="year" tagx="year" title="year">2013</span>;<span class="volume" tagx="volume" title="volume">29</span>:<span class="fpage" tagx="fpage" title="fpage">3073</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/24048355">24048355</a></span></span></li> <li tag="ref"><a name="CIT0037" /><span class="label" tagx="label" title="label">37</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ding</span><span class="given-names" tagx="given-names" title="given-names">L</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cao</span><span class="given-names" tagx="given-names" title="given-names">J</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lin</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer</span>. <span class="source" tagx="source" title="source">Int J Mol Sci</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">21</span>:<span class="fpage" tagx="fpage" title="fpage">1960</span>.</span></li> <li tag="ref"><a name="CIT0038" /><span class="label" tagx="label" title="label">38</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Daina</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Michielin</span><span class="given-names" tagx="given-names" title="given-names">O</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zoete</span><span class="given-names" tagx="given-names" title="given-names">V.</span></span></span><span class="mixed-article-title" title="mixed-article-title">SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</span>. <span class="source" tagx="source" title="source">Sci Rep</span><span class="year" tagx="year" title="year">2017</span>;<span class="volume" tagx="volume" title="volume">7</span>:<span class="fpage" tagx="fpage" title="fpage">42717</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/28256516">28256516</a></span></span></li> <li tag="ref"><a name="CIT0039" /><span class="label" tagx="label" title="label">39</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Daina</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Zoete</span><span class="given-names" tagx="given-names" title="given-names">V.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules</span>. <span class="source" tagx="source" title="source">ChemMedChem</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">11</span>:<span class="fpage" tagx="fpage" title="fpage">1117</span>â€"<span class="lpage" tagx="lpage" title="lpage">21</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27218427">27218427</a></span></span></li> <li tag="ref"><a name="CIT0040" /><span class="label" tagx="label" title="label">40</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Veber</span><span class="given-names" tagx="given-names" title="given-names">DF</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Johnson</span><span class="given-names" tagx="given-names" title="given-names">SR</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Cheng</span><span class="given-names" tagx="given-names" title="given-names">HY</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Molecular properties that influence the oral bioavailability of drug candidates</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2002</span>;<span class="volume" tagx="volume" title="volume">45</span>:<span class="fpage" tagx="fpage" title="fpage">2615</span>â€"<span class="lpage" tagx="lpage" title="lpage">23</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/12036371">12036371</a></span></span></li> <li tag="ref"><a name="CIT0041" /><span class="label" tagx="label" title="label">41</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lipinski</span><span class="given-names" tagx="given-names" title="given-names">CA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lombardo</span><span class="given-names" tagx="given-names" title="given-names">F</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Dominy</span><span class="given-names" tagx="given-names" title="given-names">BW</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Feeney</span><span class="given-names" tagx="given-names" title="given-names">PJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings</span>. <span class="source" tagx="source" title="source">Adv. Drug Deliv. Rev</span><span class="year" tagx="year" title="year">2001</span>;<span class="volume" tagx="volume" title="volume">46</span>:<span class="fpage" tagx="fpage" title="fpage">3</span>â€"<span class="lpage" tagx="lpage" title="lpage">26</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11259830">11259830</a></span></span></li> <li tag="ref"><a name="CIT0042" /><span class="label" tagx="label" title="label">42</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Egan</span><span class="given-names" tagx="given-names" title="given-names">WJ</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Merz</span><span class="given-names" tagx="given-names" title="given-names">KM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baldwin</span><span class="given-names" tagx="given-names" title="given-names">JJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Prediction of Drug Absorption Using Multivariate Statistics</span>. <span class="source" tagx="source" title="source">J. Med. Chem</span><span class="year" tagx="year" title="year">2000</span>;<span class="volume" tagx="volume" title="volume">43</span>:<span class="fpage" tagx="fpage" title="fpage">3867</span>â€"<span class="lpage" tagx="lpage" title="lpage">77</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11052792">11052792</a></span></span></li> <li tag="ref"><a name="CIT0043" /><span class="label" tagx="label" title="label">43</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ghose</span><span class="given-names" tagx="given-names" title="given-names">AK</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Viswanadhan</span><span class="given-names" tagx="given-names" title="given-names">VN</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Wendoloski</span><span class="given-names" tagx="given-names" title="given-names">JJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases</span>. <span class="source" tagx="source" title="source">J Comb Chem</span><span class="year" tagx="year" title="year">1999</span>;<span class="volume" tagx="volume" title="volume">1</span>:<span class="fpage" tagx="fpage" title="fpage">55</span>â€"<span class="lpage" tagx="lpage" title="lpage">68</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/10746014">10746014</a></span></span></li> <li tag="ref"><a name="CIT0044" /><span class="label" tagx="label" title="label">44</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Muegge</span><span class="given-names" tagx="given-names" title="given-names">I</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Heald</span><span class="given-names" tagx="given-names" title="given-names">SL</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Brittelli</span><span class="given-names" tagx="given-names" title="given-names">D.</span></span></span><span class="mixed-article-title" title="mixed-article-title">Simple selection criteria for drug-like chemical matter</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2001</span>;<span class="volume" tagx="volume" title="volume">44</span>:<span class="fpage" tagx="fpage" title="fpage">1841</span>â€"<span class="lpage" tagx="lpage" title="lpage">6</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/11384230">11384230</a></span></span></li> <li tag="ref"><a name="CIT0045" /><span class="label" tagx="label" title="label">45</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Baell</span><span class="given-names" tagx="given-names" title="given-names">JB</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Holloway</span><span class="given-names" tagx="given-names" title="given-names">GA.</span></span></span><span class="mixed-article-title" title="mixed-article-title">New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays</span>. <span class="source" tagx="source" title="source">J Med Chem</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">53</span>:<span class="fpage" tagx="fpage" title="fpage">2719</span>â€"<span class="lpage" tagx="lpage" title="lpage">40</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/20131845">20131845</a></span></span></li> <li tag="ref"><a name="CIT0046" /><span class="label" tagx="label" title="label">46</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ruth</span><span class="given-names" tagx="given-names" title="given-names">B</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Schipani</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">James</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Lessons learnt from assembling screening libraries for drug discovery for neglected diseases</span>. <span class="source" tagx="source" title="source">ChemMedChem</span><span class="year" tagx="year" title="year">2008</span>;<span class="volume" tagx="volume" title="volume">3</span>:<span class="fpage" tagx="fpage" title="fpage">435</span>â€"<span class="lpage" tagx="lpage" title="lpage">44</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/18064617">18064617</a></span></span></li> <li tag="ref"><a name="CIT0047" /><span class="label" tagx="label" title="label">47</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Sabt</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Abdelhafez</span><span class="given-names" tagx="given-names" title="given-names">OM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">El-Haggar</span><span class="given-names" tagx="given-names" title="given-names">RS</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: Synthesis, inÂ vitro biological evaluation, and QSAR studies</span>. <span class="source" tagx="source" title="source">J Enzym Inhib Med Chem</span><span class="year" tagx="year" title="year">2018</span>;<span class="volume" tagx="volume" title="volume">33</span>:<span class="fpage" tagx="fpage" title="fpage">1095</span>â€"<span class="lpage" tagx="lpage" title="lpage">107</span>.</span></li> <li tag="ref"><a name="CIT0048" /><span class="label" tagx="label" title="label">48</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hassan</span><span class="given-names" tagx="given-names" title="given-names">GS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Rashood</span><span class="given-names" tagx="given-names" title="given-names">ST</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Synthesis and inÂ vitro anticancer activity of certain novel 1-(2-methyl-6-arylpyridin-3-yl)-3-phenylureas as apoptosis-inducing agents</span>. <span class="source" tagx="source" title="source">J Enzym Inhib Med Chem</span><span class="year" tagx="year" title="year">2019</span>;<span class="volume" tagx="volume" title="volume">34</span>:<span class="fpage" tagx="fpage" title="fpage">322</span>â€"<span class="lpage" tagx="lpage" title="lpage">32</span>.</span></li> <li tag="ref"><a name="CIT0049" /><span class="label" tagx="label" title="label">49</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Hassan</span><span class="given-names" tagx="given-names" title="given-names">GS</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Al-Rashood</span><span class="given-names" tagx="given-names" title="given-names">ST</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Marine-inspired bis-indoles possessing antiproliferative activity against breast cancer; design, synthesis, and biological evaluation</span>. <span class="source" tagx="source" title="source">Mar Drugs</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">18</span>:<span class="fpage" tagx="fpage" title="fpage">190</span>.</span></li> <li tag="ref"><a name="CIT0050" /><span class="label" tagx="label" title="label">50</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Said</span><span class="given-names" tagx="given-names" title="given-names">MA</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Eldehna</span><span class="given-names" tagx="given-names" title="given-names">WM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Nocentini</span><span class="given-names" tagx="given-names" title="given-names">A</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Sulfonamide-based ring-fused analogues for CAN508 as novel carbonic anhydrase inhibitors endowed with antitumor activity: design, synthesis, and inÂ vitro biological evaluation</span>. <span class="source" tagx="source" title="source">Eur J Med Chem</span><span class="year" tagx="year" title="year">2020</span>;<span class="volume" tagx="volume" title="volume">189</span>:<span class="fpage" tagx="fpage" title="fpage">112019</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/31972394">31972394</a></span></span></li> <li tag="ref"><a name="CIT0051" /><span class="label" tagx="label" title="label">51</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Ayaz</span><span class="given-names" tagx="given-names" title="given-names">P</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Andres</span><span class="given-names" tagx="given-names" title="given-names">D</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Kwiatkowski</span><span class="given-names" tagx="given-names" title="given-names">DA</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Conformational adaption may explain the slow dissociation kinetics of roniciclib (BAY 1000394), a type I CDK inhibitor with kinetic selectivity for CDK2 and CDK9</span>. <span class="source" tagx="source" title="source">ACS Chem Biol</span><span class="year" tagx="year" title="year">2016</span>;<span class="volume" tagx="volume" title="volume">11</span>:<span class="fpage" tagx="fpage" title="fpage">1710</span>â€"<span class="lpage" tagx="lpage" title="lpage">9</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/27090615">27090615</a></span></span></li> <li tag="ref"><a name="CIT0052" /><span class="label" tagx="label" title="label">52</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Trott</span><span class="given-names" tagx="given-names" title="given-names">O</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Olson</span><span class="given-names" tagx="given-names" title="given-names">AJ.</span></span></span><span class="mixed-article-title" title="mixed-article-title">AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading</span>. <span class="source" tagx="source" title="source">J Comp Chem</span><span class="year" tagx="year" title="year">2010</span>;<span class="volume" tagx="volume" title="volume">31</span>:<span class="fpage" tagx="fpage" title="fpage">455</span>â€"<span class="lpage" tagx="lpage" title="lpage">61</span>.<span class="pub-id"><a href="http://www.ncbi.nlm.nih.gov/pubmed/19499576">19499576</a></span></span></li> <li tag="ref"><a name="CIT0053" /><span class="label" tagx="label" title="label">53</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Morris</span><span class="given-names" tagx="given-names" title="given-names">GM</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Huey</span><span class="given-names" tagx="given-names" title="given-names">R</span></span>, <span class="name" tagx="name" title="name"><span class="surname" tagx="surname" title="surname">Lindstrom</span><span class="given-names" tagx="given-names" title="given-names">W</span></span>, <span class="etal" title="etal"><i>et al.</i></span></span><span class="mixed-article-title" title="mixed-article-title">Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity</span>. <span class="source" tagx="source" title="source">J Comp Chem</span><span class="year" tagx="year" title="year">2009</span>;<span class="volume" tagx="volume" title="volume">16</span>:<span class="fpage" tagx="fpage" title="fpage">2785</span>â€"<span class="lpage" tagx="lpage" title="lpage">91</span>.</span></li> <li tag="ref"><a name="CIT0054" /><span class="label" tagx="label" title="label">54</span><span class="mixed-citation" tagx="mixed-citation" title="mixed-citation"><span class="person-group'"><span class="collab'">collab: Available online</span></span>: <a href="https://3dsbiovia.com/resource-center/downloads/">https://3dsbiovia.com/resource-center/downloads/</a> [last accessed 10 April 2020].</span></li> </ul> </div> </div>  </body></html>